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chapter I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
1.1. Introduction. 
Vitamin B12 plays a unique role in mammalian metabolism 
not only because, as a coenzyme, it is involved in two 
completely different and unrelated biochemical pathways, -
the synthesis of nucleic acid precursors and the catabolism 
of some fatty acids -, but even more because it gives an 
excellent example how different groups of living organisms 
work together and depend on each other for the supply of 
vital nutrients. Vitamin B12 is almost exclusively found in 
animal products. However, it is not synthesized by the 
animals themselves but, they are able in one or the other 
way to absorb vitamin B12 which is produced bv micro-
organisms. For instance in ruminants the bacteria in the 
rumen are the source of the vitamin, which is taken up by 
the gut, distributed over the tissues and which is 
subsequently consumed by man with the meat or with the milk. 
However, the quantity of vitamin B12 , which is available in 
the food. is so low, that it would be lost if not an 
elaborate system of carrier proteins and cellular receotor 
mechanisms selectively collected it from the food and 
delivered it to the tissues. Intrinsic factor, produced and 
secreted by the qastric mucosa, binds the vitamin, which 
enters the body with the food, and hands it over to the 
ileal mucosa cells, which carry specific receptors for this 
protein. When the vitamin enters the blood, t_he plasma 
transport proteins, the transcobalamins, take it up 
immediately and deliver it to the tissues. 
It was the object of the investigations, which are 
presented in this thesis, to reveal the mechanism of this 
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delivery and to obtain a comprehensive picture of the 
various aspects of the cellular uptake. The rat liver cell 
was chosen for this purpose as an in vitro model, not only 
because established methods are available for the isolation 
of cellular subtractions and of intact viable cells, but 
also because the liver is one of the main storage pools for 
vitamin B12 of the body and has possibly a regulatory 
function in the maintenance of the blood vitamin B12 level. 
Section 1.2. reviews the literature on vitamin B12 and 
its binding proteins. It is, evidently, not exhaustive, but 
the major steps in the progress of the understanding of 
vitamin B12 transport and metabolism are outlined. 
1.2. Literature. 
1.2.1. Historical review on vitamin B12 investigations. 
The history of vitamin B12 begins with the first 
description of what appears to have been pernicious anemia 
by J.S. Combe in 1822 (l). In 1849 Th. Addison (2) 
described a case of idiopathic anemia, which since then has 
been regarded as a classic picture of severe pernicious 
anemia. The name of the disease was introduced by Biermer in 
1872 (3). In the years thereafter increasing evidence was 
collected for a connection between the gastric and the 
hematological phenomena in this disease and thanks to the 
advance in morphological techniques a better description of 
the megaloblastic changes in the bone marrow was obtained 
by Cohnheim in 1876 (4), Ehrlich in 1880 (5), Cabot in 1903 
(6) and Ehrlich in 1905 (7), and the atrophic appearance of 
the gastric mucosa was revealed by Fenwick in 1870 (8) and 
Cahn and von Mering in 1886 (9). 
However, it lasted until 1926 before the first 
therapeutic results were obtained. Using the experimental 
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Fig. 1.1. Structural formula of vitamin B12 . 
data from Whipple, Robscheit and Hooper (10), who observed 
that liver was a potent hematopoietic substance in 
experimentally anemic dogs, Minot and Murphy (11) treated 
successfully a patient with severe pernicious anemia with 
large amounts of raw liver. 
The involvement of a gastric factor in the therapeutic 
effect of the liver diet was first demonstrated by Castle 
in 1929 (12), who reported the benificial effect of normal 
human gastric juice on the therapeutic results of a beef 
diet in pernicious anemia patients. In subsequent reports 
Castle supposed the production of an "intrinsic factor" by 
the human stomach. The "extrinsic" counterpart was assumed 
to be present in the liver or beef diet. 
In 1948 the extrinsic factor, named vitamin B12 , was almost 
at the same time isolated in pure form by Folkers et al. 
(13) in the United States and by Smith in England (14). 
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In 1956 Hodgkin et al. (15) revealed the structure of 
the vitamin B12 molecule by means of x-ray cristallography 
(figure 1.1). Finally in 1972 the last basic step in the 
identification of the ''extrinsic factor'' was set by 
R.B. Woodward (16), who succeeded in the complete synthesis 
of a biologically active vitamin B12 . 
An important advance in the research on vitamin B12 
transport in the body was made possible by the work of 
Chaiet, Rosenblum and woodbury in 1950 (17), who incorpora-
ted radioactive cobalt isotopes in the vitamin B12 molecule 
with microbiological techniques. In the first place it 
became possible to measure the ability of animals or 
patients to absorb vitamin B12 (18 - 21). Secondly progress 
was made in the purification of Castle's intrinsic factor, 
which is necessary for normal vitamin B12 absorption, by 
Ellenbogen et al. (22), Grasbeck et al. (23) and Chosy and 
Schilling (24). 
Definite physicochemical analysis could be performed 
after complete purification of intrinsic factor was reached 
first by Grasbeck et al. in 1966 (25) using conventional 
techniques and later by Christensen et al. (26) and Allen 
et al. (27) in 1973, using affinity chromatography. 
Intrinsic factor appeared to be a glycoprotein with a 
molecular weight of 44 000, based on aminoacid and carbo-
hydrate composition. It is very selective in its binding of 
vitamin B12 molecules; cyano-, hydroxo-, methyl-, ond 
adenosyl-cobalamin are all bound with about the same 
association constant of 10 10 M- 1 , but cobalamins with 
altered or lacking nucleotide portions show markedly 
decreased binding (27). 
The availability of radioactive vitamin B12 made it 
possible to study many other aspects of the transport and 
metabolism of vitamin B12 , which will be reviewed in the 
following sections. 
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1.2.2. Absorption of vitamin B12 . 
Vitamin B12 from the food is bound to intrinsic factor, 
which is secreted with the gastric juice, and the complex 
attaches to specific binding sites on the surface membrane 
of the epithelial cells in the distal part of the ileum (28). 
The demonstration of Veeger et al. (29) that patients with 
pancreatic insufficiency exhibit a malabsorption of vitamin 
B12 and similar observations in our laboratory with dogs 
suggest that pancreatic enzymes are necessary for the 
removal of inhibitory substances or competitive binding 
proteins or for the activation of intrinsic factor as 
suggested by Abels et al. (30). Allen et al. (31) reported 
that at least in man the pancreatic enzymes play a role in 
the destruction of non-intrinsic factor vitamin B12-binding 
proteins in saliva and gastric juice. The vitamin B12 , which 
is almost completely bound to this type of proteins, then 
becomes available for intrinsic factor binding and 
subsequent absorption. The binding of IF-vitamin B12 to 
receptors on the brush borders of the ileal mucosa cell is 
the first step in the absorption process (32). This receptor 
was solubilized and characterized to some extent by Katz and 
Cooper in 1972 (33) and others (34 - 36). It is not clear 
what happens after binding to the receptors. The cellular 
uptake requires energy and it has been suggested that the 
total complex is taken up by the cells in a pinocytotic 
process (37). Some of the absorbed vitamin B12 is found 
in the mitochondria 2 hours after an oral dose of radio-
active vitamin B12 (38). A part of the vitamin B12 seems to 
be converted to its coenzyme forms but another part reaches 
the blood unchanged (39}. The fate of the intrinsic factor 
molecule is unknown. Vitamin B12 is released in the portal 
circulation with a delay of several hours and there is 
conflicting information on whether it is released in the 
free form (40) or bound to transcobalamin II (41). 
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Only ten years after the first isolation of vitamin 
B12 , it was discovered that cyanocobalamin and hydroxo-
cobalamin were not the active forms, which take part in 
cellular metabolism. The extremely low concentration of the 
real coenzyme forms in the tissues and their sensitivity to 
light, leading to rapid conversion to hydroxocobalamin, 
account for this. In 1958 Barker et al. (42) isolated the 
5'-deoxyadenosyl-cobalamin or coenzyme B12 , and in 1964 
Lindstrand (43) and Stahlberg (44) detected methylcobalamin 
by chromatographic analysis of plasma and liver extracts. 
Coenzyme B12 functions in the methylmalonyl-Co A mutase 
dependent reaction, in which methylmalonyl-Co A is converted 
to succinyl-Co A {45) and is thereby involved in the cata-
bolism of branched chain and odd numbered fatty acids, some 
amino acids and thymine. Deficiency of the coenzyme leads 
to an increase in the excretion of methylmalonic acid and 
propionic acid in the urine. 
Methylcobalamin takes part as a coenzyme in a complica-
ted methylgroup transfer reaction, in which the methylgroup 
of methyltetrahydrofolic acid is transfered to homocysteine 
under the formation of methionine, whereas s-adenosyl 
methionine is needed as a cofactor. This reaction forms a 
link between sulphur-aminoacid metabolism and folate 
metabolism. Deficiency of the coenzyme leads to an 
accumulation of methyltetrahydrofolate and homocysteine and 
a shortage of methionine. The accumulation of methyltetra-
hydrofolate and concomittant reduction of tetrahydrofolate, 
the product of this reaction, causes an impairment of the 
synthesis of purines, and in particular of the synthesis 
of thyrnidylate from uridylate, because the folate 
derivatives, which are involved in these pathways are 
synthesized from tetrahydrofolate. 
In this way vitamin B12 is related to the biosynthesis 
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of DNA precursors and a· deficiency of vitamin B12 results, 
similar to a deficiency of folate, ultimately in decreased 
DNA synthesis and impaired cell division. The observations 
on the interrelationship of vitamin B12 and folic acid 
through the methyltransferase reaction were summarized in 
the so-called methylfolate trap hypothesis which was 
introduced in 1962 by Herbert and Zalusky {46) and Noronha 
and Silverman (47). 
1.2.4. Transport of vitamin B12 . 
After absorption of vitamin B12 by the epithelial cells 
of the ileal mucosa, the molecule is transported through the 
cell into the portal blood system and immediately bound to 
specific plasma transport proteins. The first report about 
plasma vitamin B12 binding proteins was from Pitney et al. 
(48) who described that en~ogenous vitamin B12 is largely 
present in the a-globulin fraction of plasma proteins. 
Miller and Sullivan (49) found that both in the a 1-globulin 
and S-globulin fraction binding of vitamin B12 took place 
and that in chronic granulocytic leukemia the vitamin B12 
binding capacity of a 2-globulin fraction was highly 
increased. 
Experiments of Hall and Finkler (50,51) with 
intravenously injected vitamin B12 showed that vitamin B12 
bound to the beta-globulin fraction disappeared much faster 
from the blood than vitamin B12 bound to the a 1-globulin 
fraction. The beta-globulin binder, which t~ey called trans-
cobalamin II, to distinguish it from the a 1-globulin binder, 
which was called transcobalamin I, was thought to function 
at an earlier stage of vitamin B12 distribution than the 
a 1-globulin binder and to be important in the movement of 
vitamin B12 from intestine to tissue. 
In 1969 a third binding protein in serum was described 
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by Lawrence (52) . This binding protein has the molecular 
weight of transcobalamin I (TC I) and the electrophoretic 
mobility of transcobalamin II (TC II) and was named 
transcobalamin III (TC III) (53,54). In contrast to TC I the 
new binder exhibited the ability to transport vitamin B12 to 
the liver (55). 
Different names for the vitamin B12 binding proteins 
were used. Gullberg (56) proposed transcobalamin large 
(TC L) for TC I and TC III and transcobalamin small (TC S) 
for TC II. Based on the electrophoretic mobility TC I and 
III were also called R-binders (rapid mobility). The R-
binders are present in almost all body fluids and precise 
analysis of the protein from the different sources revealed 
that they are immunologically identical(57) and that the 
amino acid composition is the same for all R-binders, 
suggesting a common peptide backbone (58). Variation in 
carbohydrate composition and structure is held responsible 
for the microheterogeneity in isoelectric point (59,60). The 
distinction between TC I and TC III is therefore artificial, 
TC I is the acidic fraction of the R-prQteins or cobalo-
philins, as they were named by Stenman (60) and TC III is 
the more basic fraction. Cobalophilins from granulocyte 
lysate, which are indistinguishable from the plasma TC III 
fraction, have a short half life in the circulation and seem 
to deliver their bound vitamin B12 exclusively to the liver 
(61,62), which confirms earlier observations of Toporek et 
al. (55). The presence of cobalophilin in granulocytes and 
the tendency of these cells to release these binding 
proteins during serum preparation (56), have caused much 
confusion in the determination of the vitamin B12 -binding 
capacity of the TC III fraction in sera from normal and 
leukemic patients. Carmel (63) has recently lined up the 
differences between measurements in plasma and in serum and 
the effects of various anticoagulants with respect to the 
vitamin B12 -binding capacity of the three transcobalamins. 
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He concluded that the most reliable results are obtained 
with NaF/EDTA plasma and that the concentration of TC III 
is generally very low in normal plasma and only moderately 
elevated in polycythemia vera and chronic myelogenous 
leukemia. Highly elevated levels of TC I were found in 
plasma from patients with chronic myelogenous leukemia, 
leukocytosis and several forms of cancer. 
The function of cobalophilins is still obscure, 
especially because no clinical symptoms were found in two 
patients which had a deficiency of all cobalophilins (64) 
Cobalophilins are not found in the rat and the mouse and 
their only plasma transport protein is transcobalamin II. 
In these animals all endogenous vitamin B12 is bound to this 
protein and there is a relatively large unsaturated vitamin 
B12 -binding capacity. Cooper and Parenchych (65) described 
the uptake of vitamin B12 by human and mouse ascites tumor 
cells and this uptake was completely dependent on the 
presence of transcobalamin II. This suggested that trans-
cobalamin II is not only involved in transport of vitamin 
B12 through the blood but also takes part in the uptake 
mechanism of the tissues. This vital role of TC II in the 
delivery of vitamin B12 to the tissues was proven by the 
observations on patients with a congenital deficiency of 
TC II, who, despite a normal serum vitamin B12 concentration, 
developed a severe megaloblastic anemia which could only be 
corrected by frequent parenteral injections of large amounts 
of vitamin B12 (66 - 68). 
More recent developments in the studies on the cellular 
uptake of vitamin B12 are discussed in section 1.2.6. 
1.2.5. Purification and characterization of transcobalamin 
------------------------
II. 
The isolation of transcobalamin II from plasma in a 
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pure form is severely hampered by the very low concentration, 
25 ~g/1, of this vitamin B12-transport protein. Rat and 
mouse plasma have higher concentrations but in these animals 
the availability of the plasma is a limiting factor. 
A second problem in the purification of TC II is the 
unstability of the protein. At low salt concentrations the 
protein tends to aggregate and at a pH below 5.5 
irreversible loss of vitamin B12-binding capacity occurs. 
All these circumstances make it very difficult to purify 
TC II with an acceptable yield by means of conventional 
separation methods. Puutula and Grasbeck (69) nevertheless 
reached a purification index of about 10 6 with a yield of 
2.2%. Starting from 25 kg Cohn fraction III, subsequent 
CM-cellulose batchwise elution, DEAE-cellulose batchwise 
elution, recycling chromatography on sephadex G100, armnonium 
sulphate precipitation, DEAE-cellulose column chromatography~ 
calcium phosphate gel chromatography, and immunoadsorption 
were carried out and the total product was characterized 
functionnally by the stimulation of the vitamin B12 uptake 
by erythrocytes and Hela cells. The Stokes re.dius of the 
isolated protein was computed at 25.5 A , the molecular 
weight with gel filtration was 38 000 and with sedimentation 
equilibrium ultra centrifugation 28 500 and 30 100. The 
isoelectric points were 6.2-6.3 and 6.4-6.5; the minimum 
value of the 280/361 nm extinction ratio was 3.43. The 
protein was thought to be a glycoprotein with 13.0% neutral 
hexoses but no sialic acid. It was assumed that about 30% 
of the total protein was transcobalamin II-vitamin B12 
complex, whereas the remainder was supposed to be partly 
unsaturated binder. 
In 1972 Allen and Majerus published a major improvement 
by the use of affinity chromatography for the purification 
of TC II (70). A monocarboxylic derivative of cyanocobalamin 
was covalently coupled to 3.3'-diaminodipropylamine-
substituted Sepharose using carbodiimide. 72 kg Cohn 
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fraction III from human plasma were dissolved and TC II was 
extracted with CM-Sephadex. The CM-Sephadex eluate was 
applied to a 10 ml cyanocobalamin-Sepharose column which 
was intensively rinsed with a variety of buffer systems. 
Finally the linkage between the immobilized ligand and the 
binding protein was broken by the denaturing effect of a 
7.5 M guanidine solution. To remove the contaminating 
proteins, which were still present, the eluate was subse-
quently subjected to DEAE-cellulose 1 3.3'-diaminodipropyl-
amine-Sepharose and Sephadex G150 chromatography. The final 
product had a specific binding activity of 28.6 ~g vitamin 
B12 /mg protein and was 2.10
6 fold purified with a yield of 
12.8%. The 280/361 nm ratio was 2.04. The pure product was 
homogeneous in polyacrylamide gel electrophoresis, sedimen-
tation equilibrium centrifugation, gel filtration, and the 
ratio of total amino acid content to bound vitamin B12 . 
A surprising result was obtained with the determination 
of the molecular weight, namely 59 500 on amino acid 
analysis and 53 900 and 60 000 with sedimentation equili-
brium centrifugation. In a later publication (71) Allen 
corrected this observation and confirmed the molecular 
weight of 38 000 found in other studies. The explanation for 
the higher molecular weight in the first report was probably 
the aggregation of a polypeptide fragment of TC II with 
a molecular weight of 25 000 with an intact molecule of 
38 000. This fragment had probably arisen by proteolysis 
before or during the purification procedure. In contrast 
to the observations of Puutula and Grasbeck (69), no carbo-
hydrates were found in the pure preparation, which indicated 
that TC II is not a glycoprotein. 
In 1975 Nex¢ (72) presented another affinity chromato-
graphy technique for vitamin B12 binding proteins which 
made use of the property of hydroxocobalamin to form a 
thermolabile linkage with 3.3'-diaminodipropylamine. The 
elution of the protein from the affinity column was obtained 
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by an elevation of the temperature, instead of the protein 
denaturation by guanidine as used by Allen (70). With this 
technique rabbit transcobalamin II was purified and 
characterized by Nex¢ et al. (73). Although no solid 
evidence was given for the purity of their preparation, the 
given analytical data are in agreement with those reported 
by Allen (70). Rabbit and human TC II showed to have a 
similar overall amino acid composition and the N-terminal 
sequence was found to be different from that of transcobala-
min I and intrinsic factor, except for the first three amino 
acids which were the same for TC I and TC II. 
The similarity between TC II molecules from different 
animal species regarding immunological and biological 
properties was described by Tan and Blaisdell (74). 
Mammalian TC II showed a high degree of mutual cross-
reactivity, but avian,amphibian, reptilian and piscine TC II 
did not cross-react with anti-rabbit TC II. Regarding the 
biological activities of mammalian TC II towards reticulo-
cytes or erytrocytes from different mammalian species, ell 
preparations stimulated the binding of vitamin B12 to the 
cells but there was a great variation in the degree of 
promotion. 
1. 2. 6 fe!l~l~r_u:e_t~k~ 
vitamin B12 . 
and metabolism of transcobalamin II-
----------------
It was concluded from the data in section 1.2.4. that 
in vivo transcobalamin II plays a vital role in the trans-
fer of vitamin B12 to the tissue. Also in vitro, trans-
cobalamin II mediated the uptake of vitamin B12 by cells, 
for instance by reticulocyte-rich erythrocyte suspension 
(75) and by Hela cells (76). The uptake of transcobalamin 
II-vitamin B12 was believed to consist of a primary stage, 
in which binc~ing of the complex to the cell surface takes 
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place, and a secondary phase, in which the transport of 
vitamin B12 into the cells occurs. An exception of the rule 
that TC II-bound vitamin B12 is taken up in higher amounts 
than free vitamin B12 seems to be the kidney. Perfusion of 
dog kidney with either free or TC II-bound vitamin B12 
showed that larger amounts of free than of bound vitamin B12 
were retained, possibly by reabsorption in the tubuli (77). 
In vivo experiments with mice by Tan et al. (78) showed 
that with the uptake of TC II-vitamin B12 by the tissues the 
TC II is consumed. The level of TC II must therefore be 
maintained by de novo synthesis of the carrier protein. 
Heart and spleen were quite effective in the removal of 
TC II-vitamin B12 and free vitamin B12 from the perfusion 
medium in experiments of Hall and Rappazzo (79). The 
relatively large amount of uptake of free vitamin B12 was 
thought to be caused by production of TC II in this 
perfusion system (80). 
The production of TC II by the rat liver was 
investigated by Cooksley and Tavill (81,82), who concluded 
that there is a continuous production of TC II, which is 
independent of the presence of unsaturated or saturated 
TC II or of the free vitamin B12 concentration in the 
perfusate. The release of TC II in the medium was inhibited 
by cycloheximide. Together with the production of binding 
protein the perfused rat liver released vitamin B$1 
molecules, taken up after in vivo injections of [ co] 
vitamin B12 . The rate of release was constant and was depen-
dent on the length of time between the injection and the 
perfusion. Release of radioactive vitamin B12 in the bile 
was generally low. Cycloheximide had no effect on the 
release, nor had extracellular TC II and free vitamin B12 . 
TC II production was in 20-fold excess of the vitamin B12 
release on a molar base and there does not seem to be an 
interrelation between the release of vitamin B12 and the 
release of binding protein. 
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Kinetic aspects of TC II-vitamin B12 uptake were 
studied by Digirolamo and Huennekens (83). The uptake 
proceeded in two steps. A rapid primary step appeared to 
involve binding of the protein-vitamin complex to the cell 
membrane and had a Km of 180 pM and a capacity of about 
6 pmol/10 9 cells. This binding was hardly influenced by 
temperature and had an optimum at pH 5. Calcium was required 
for the binding but could be exchanged for magnesium. The 
second step was much slower and energy dependent. It was 
interpreted as the transfer of the vitamin to the interior 
of the cell. The velocity of this process was 0.4 pmoljmin/ 
10 9 cells. Several metabolic inhibitors were able to block 
this second phase. The authors concluded that these cells 
were able to take up vitamin s 12 through about 400 entry 
sites per cell and that each entry site could transport 
about 10 molecules of vitamin B12 per hour. The final intra-
cellular vitamin B12 concentration was about 500 times the 
extracellular concentration. Resuspension of the cells in 
TC II-vitamin B12-free medium caused a rapid release of 
vitamin B12 from the cell. This observation is in agreement 
with the data on the release of vitamin B12 from the liver 
(80,81). The factors which are involved in the release of 
vitamin s 12 from cells were investigated by Rosenberg et al. 
(84) in human fibroblasts. It was shown that the amount of 
release is at least partially dependent on the presence of 
an intracellular binding protein. Cultured fibroblasts from 
patients, who fail to synthesize both cobalamin coenzymes. 
defined as cbl C mutant, 1vere unable to retain the vitamin 
s 12 which was taken up during the incubation period. The 
intracellular protein, which bound the intracellular labeled 
vitamin in normal cells, was lacking in the cbl C mutant 
cells. 
The kinetics of uptake of TC II-vitamin B12 by L 1210 
lyrnphoblasts have also been studied by Ostroy and Garns (85) 
The incorporation of vitamin s 12 in the cells was both 
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temperature and calcium dependent and was inhibited by apo-
TC II (unsaturated binding protein) . The Km of the transport 
process was 2.5 x 10-9M at 37°C. Again it was observed that 
the intracellular vitamin B12 could be almost completely 
released by the cells. The release was found to be 
temperature dependent: zero at 4°C and maximal at 37°C, and 
independent of calcium. The released vitamin B12 was either 
bound to TC II or to a protein with chromatographic proper-
ties similar to cobalophilins. 
In view of their former results with the TC II 
dependent uptake of vitamin B12 by isolated rat liver 
mitochondria (86) Ostroy et al. expressed their doubts about 
the ·assumption that the complex, after attachment to the 
plasma membrane, is transfered into the cell by pinocytosis 
followed by lysosomal fusion and subsequent proteolysis of 
TC II. This model was proposed by Pletsch and Coffey (87) 
on the basis of studies with liver fractionation after 
intravenous injections of [ 57co)cyanocobalamin. At 5 min 
after the injection TC II-bound vitamin B12 was recovered 
in the plasma membrane fraction and at 30 min significant 
amounts of TC II-bound vitamin B12 were found in the lyse-
somes. At later points of time, vitamin B12 was mainly 
present in the soluble and mitochondrial compartment, but 
it was no longer bound to TC II. These observations sugges-
ted a dissociation of vitamin B12 from TC II at the level 
of the lysosomal system, but in the absence of a label in 
the protein moiety of the complex the proteolysis of TC II 
could not be proven. 
The incorporation of a protein label became possible 
after the complete purification of TC II by Allen et al. 
(70), and the fate of pure 125 r-labeled TC Ir-[ 57co] CN-Cbl 
was studied after intravenous injections into rabbits (88). 
[ 57 l 125 The Co CN-Cbl and the I-label were cleared from 
circulation at about the same rate and after 15-30 min 
the 
l25I-
labeled small molecular weight-compounds were detected in 
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the plasma and excreted in the urine. This observation shows 
that in these experimental conditions TC II is broken down 
by the tissues and confirms the model as proposed by Pletsch 
et al. (87). It was also noticed that a considerable part of 
the vitamin B12 re-entered the circulation. 
Further elucidation of the way of entry and intracellu-
lar transport of TC II-vitamin B12 was given by Youngdahl-
Turner et al. (89). Human fibroblasts were incubated with 
[125I] TC II-[ 57co] vitamin B12 under various circumstances. 125I- and 57co-radioactivity were taken up by the cells 
almost at the same rate. [ 57co] vitamin B12 was incorporated 
in the earlier mentioned large molecular weight binding 
protein (84) . The 125I-label reappeared in the medium with 
a lag of 2 hours as small molecular weight degradation 
products, as a result of intracellular degradation of TC II 
in the fibroblasts. The involvement of the lysosomes in this 
degradation process was further made plausible by the 
inhibition of proteolysis after the addition of the lyso-
somotropic agent chloroquine to the medium, which on the one 
hand caused a complete inhibition of proteolysis and on the 
other hand resulted in an accumulation of radioactivity 
inside the cell. Probably the digestion of the complex in 
the cell was blocked at the level of the lysosomes. 
In conclusion there are no doubts about the crucial 
role of transcobalamin II in the transfer of vitamin B12 
from the blood plasma to the tissues. A variety of tissues 
and cell types in different animal species internalize 
vitamin B12 from the surrounding medium much more efficiently, 
when it is bound to transcobalamin II than when it is free 
or bound to other vitamin B12-binding proteins. Moreover it 
seems to be physiologically irrelevant to study the uptake 
of free vitamin B12 by the tissue cells, because free 
vitamin B12 is cleared rapidly by the kidneys. 
The way of entry, however, is subject to some different 
views. On the one hand there is the hypothesis of pinocy~o-
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sis with lysosomal fusion and subsequent proteolysis of the 
carrier protein, which was originally based on the 
observations of Pletsch and Coffey (87) and further exten-
ded by the work of Allen and coworkers (88,89). On the other 
hand Gams and coworkers (85,86) have paid much attention to 
the intracellular presence of TC II and the TC II dependent 
uptake of vitamin B12 by isolated mitochondria. The latter. 
investigators did not present a clear model for the way of 
entry but assumed that the intact complex enters the cyto-
plasma. Vitamin B12 can then either leak out of the cell or 
be taken up in the mitochondria. The fate of the carrier 
protein .after internalization has not been investigated 
further. 
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chapter 2 
GENERAL METHODS 
2.1. Materials. 
The following radioactively labeled compounds were 
obtained from the Radiochemical Centre, Amersham, England: 
cyano [ 57 co] cobalamin, code CT 2, specific activity 185-210 
mCi/mg; iodine-125, code IMS 30, carrier free; [ 3H] inulin, 
code TRA 324, specific activity 695 mCi/mmol. (Methoxy- 3H] 
dextran was purchased from New England Nuclear, Boston, Mass. 
code NET-427 B, specific activity 286.3 mCi/g. Cyano [ 57 co] 
cobalamin was also obtained from Philips-Duphar, Petten, 
Holland, code DRN 2716, specific activity 185-210 mCi/mg. 
Chromatography materials, Sephadex G 50, G 75, G 150, 
G 200, Sephacryl S 200 superfine, CM-Sephadex, DEAE-
Sepharose CL-6B, CNBr-activated-Sepharose and AH-Sepharose 
were from Pharmacia Fine Chemicals, Uppsala, Sweden. 
Dulbecco's modified minimal essential tissue culture 
medium (DMEM) was purchased from Grand Island Biological 
Company (GIBCO), Paisley, Scotland or from Flow Laboratories 
Irvine, Scotland. 
Cyanocobalamin (CN-Cbl) was from Merck, hydroxocobala-
min (OH-Cbl) from Sigma. All other reagents were of analy-
tical grade purity. 
Male Wistar rats from the animal breeding farm of TNO 
(Zeist, the Netherlands) were given food and water ad 
libitum. Blood was collected under ether anesthesia by 
cannulation of the abdominal aorta. The collected blood was 
allowed to coagulate and the serum was obtained by centri-
fugation (10 min at 2 000 x g). The supernatant was centri-
fuged again at 100 000 x g for 1 hour and afterwards stored 
frozen at -20°C. 
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2.2. Measurements of vitamin B12 and vitamin B12-binding 
capacity. 
2.2.1. Preparation of vitamin B12 standard solutions. 
A solution of about 0.1 mg CN-Cbl/ml H20 was prepared 
and undissolved material was removed by filtration through 
a BUchner-funnel with filter paper S&S 589 3 . 1 ml aliquots 
were stored frozen at -80°C. The precise CN-Cbl concentration 
was determined spectrophotometrically. 4 ml CN-Cbl solution 
was diluted with 1 rnl 0.5 M NaOH, 0.5% KCN solution, and the 
absorption spectrum was measured from 370 to 240 nrn against 
0.1 M NaOH, 0.1% KCN. At this CN -concentration the cyano-
cobalamin is converted to the stable dicyanocobalamin form. 
The concentration was calculated using the molar extinction 
coefficient at the absorbance 
3 -l 30.8 X 10 M . (l). 
lcm peak at 368nm: E 368 
2.2.2. Determination of vitamin B12-binding capacity. 
Principle: the vitamin a 12-binding proteins are mixed 
with an excess of radioactively labeled CN-Cbl. The remai-
ning free vitamin B12 is removed either by coated charcoal 
or by gel filtration. The amount of protein-bound radio-
activity is a measure for the unsaturated binding capacity 
of the sample. 
Procedure: 0.2 ml samples from a serially diluted 
solution; of which the binding capacity had to be measured, 
were mixed with 0.9 ml SO mM sodium phosphate, 0.15 M NaCl, 
0.6 mM KCN, pH 7.4 and 0.2 ml of a CN-Cbl solution, 
containing 50 nCi [ 57 co] CN-Cbl per ml and CN-Cbl, adjusted 
to the expected binding capacity of the sample. After 30 min 
of incubation at room temperature the free vitamin was 
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separated frcm the bound with one of the following 
techniques: 
1. The coated-charcoal technique. (2). 
0.3 ml coated-charcoal suspension (5% activated carbon in 
0.25% dextran T 70, 0.25% bovine hemoglobin solution) 
was added and after centrifugation for 10 min at 2 000 
x g at 4°C, the amount of 57co-radioactivity in the 
supernatant was measured. After subtraction of a blank 
value, obtained from a sample without binding protein, 
the vitamin B12-binding capacity of the sample was 
calculated from the specific activity of the [57 co] CN-
Cbl solution. The amount of charcoal is chosen in such a 
way that minimal protein absorption goes together with 
optimal free vitamin absorption. However, falsely low 
values due to absorption of binding protein may occur in 
samples with a low protein content. On the contrary the 
binding capacity of samples with, for instance, much lipid 
material may be overestimated as a result of diminished 
free vitamin absorption (3,4). 
2. Gel filtration. 
The total incubation mixture was applied to a Sephadex 
G 50 column (1.6 x 35 em) and eluted with 20 mM sodium 
phosphate, 1M NaCl, buffer pH 7.4. The radioactivity in 
the 2 ml fractions was measured and the partition between 
free and bound CN-Cbl was used to calculate the Cbl-
binding capacity of the sample. Gel filtration is 
generally accepted as reference for the separation of 
free and bound vitamin B12 . It is however much more 
laborious and time-consuming than the coated charcoal 
technique. 
One molecule of vitamin B12 reacts with one molecule of 
vitamin B12-binding protein. Therefore the binding capacity, 
expressed as mol/1, reflects also the molar concentration of 
the binding proteins. 
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figure 2.1. A representative standard curve of the vitamin 
B 12 radioassay. 
2.2.3. Determination of vitamin B12 concentration. 
Principle: the used competitive protein binding 
technique was first described by Lau et al. (6). After 
destruction of binding proteins the freed vitamin B12 is 
mixed with a fixed amount of radioactive vitamin B12 . A 
binding protein 1 preferentially intrinsic factor, with a 
binding capacity for about 80% of the labeled vitamin is 
added and will bind labeled and unlabeled vitamin B12 
proportionally to their concentration in the mixture. Free 
and bound vitamin are separated with the coated charcoal 
technique. The amount of radioactivity bound in the indivi-
dual samples is expressed as the percentage of the radio-
activity bound in a sample without vitamin B12 . A standard 
curve is constructed with serial dilutions of a standard 
CN-Cbl solution. The concentration of vitamin B12 in unknown 
samples is read from this curve. 
Procedure: a series of 8 dilutions from 40 to 1200 pM 
of the standardized CN-Cbl solution (see section 2.2.1) was 
prepared in "vitamin B12-free serum" (BFS) . The BFS was made 
by boiling 1 volume of human serum 1 diluted with 4 volumes 
of 0.44 M L-glutamic acid, 0.6 mM KCN, pH 3.3 for 20 min. 
The freed vitamin was removed by passage over a Sepharose 
column, to which an excess of intrinsic factor (IF) was 
covalently coupled. All vitamin B12 was retained by the 
immobilized IF. The eluate is a perfect medium for the 
standard CN-Cbl samples because their composition becomes 
identical with the composition of unknown serum samples. 
When the vitamin B12 concentration has to be measured in 
samples with a very low protein content, for instance 
purified TC II preparations, the most reliable results are 
obtained when these samples are diluted with BFS. 
0.2 ml of a standard solution or an unknown sample was 
diluted with 0.8 ml BFS or 0.8 rnl 0.44 M L-glutamic acid, 
0.6 mM KCN, pH 3.3, boiled for 15 min and mixed thoroughly 
with 0.2 ml [ 57co] CN-Cbl (~ 45 pg). After the addition of 
0.2 ml IF solution the tubes were incubated for 45 min at 
room temperature in the dark. Hereafter 0.3 ml Hb-dextran 
coated charcoal suspension (see 2.2.2) was added and after 
10 min the sample was centrifuged for 10 min at 2 000 x g. 
The radioactivity was counted in 1 ml of the supernatant. 
The blank value (a sample without binding protein) was 
subtracted, the duplicate results were averaged and 
expressed as the percentage of radioactivity bound (p) in 
comparison with the 100% value of the zero CN-Cbl standard, 
A standard curve was composed from the known CN-Cbl samples, 
in which the Ln ~(logit) was plotted against the log 
concentration CN-Cbl. 
The concentrationS of vitamin B12 in the unknown samples 
were read from the standard curve or calculated with a 
programmable calculator. A representative standard curve is 
presented in figure 2.1. The interassay reproducibility is 
indicated by the coefficient of variation in 8 different 
independent determinations: 8% at 100 pM, 7% at 210 pM and 
4.4% at 630 pM. 
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2.3. Partial purification of transcobalamin II. 
Normal rat serum contains 555 ~ 120 pM endogenous 
vitamin B12 (mean~ S.D., n=9) and the unsaturated CN-Cbl-
binding capacity ranges from 1.7 to 2.5 nmoles/1. TC II is 
the only vitamin B12-binding protein in rat plasma and all 
endogenous vitamin B12 is bound to this protein. Partially 
purified rat TC II therefore always contains 15 to 20% of 
endogenous Cbl. For studies of binding and uptake of TC II-
Cbl it is desirable to remove the greater part of the other 
plasma proteins, because these proteins may interfere in the 
experiments. Sephadex G 150 offers a good separation of 
TC II from most of the other plasma proteins (figure 2.2) 
In this particular separation 8 ml of rat serum was 
saturated with 3.5 vCi [ 57co) CN-Cbl (~ 12 pmoles) and 
applied to the Sephadex column. Elution was carried out with 
20 rnM Tris, 1M NaCl, pH 7.4. The high salt concentration is 
necessary to avoid complexing of TC II and adsorption onto 
the chromatography material. The TC II-containing fractions 
are pooled, concentrated by ultrafiltration and dialyzed 
against the buffer solution, in which TC II has to be used 
in the respective binding or uptake studies. Further 
purification by for instance ion-exchange chromatography 
leads to considerable loss of binding activity and only 
little improvement in purity. The final product is about 
40-fold purified. 
Human plasma contains only 0.5 to 1.0 nmole TC II per 
liter and is therefore not an ideal starting material for 
a purification. However, 30 to 40% of TC II is recovered in 
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figure 2.2. Separation of 8 ml normal rat serum~ satured 
with 3.5 fJC'i { 57 co} CN-Cbl on Sephadex G 150. 
Elution buffer: 20 mM Tris~ 1M NaCZ~ pH 7.4. 
---Extinction at 280 nm;O o, 57 Co-radio-
activity. 
Cohn fraction III from human plasma. The large scale 
purification of TC II from human Cohn fraction III is 
described in chapter 5. The affinity chromatography step in 
this procedure makes it impossible to incorporate a radio-
active label with high specific activity in the vitamin 
moiety. An intermediate product from this purification, the 
CM-Sephadex eluate was prepared as follows: 20 kg Cohn 
fraction III was dissolved in 80 l of 10 mM sodium phosphate 
100 ~M NaCl pH 5.2. 100 g CM-Sephadex was added and after 
2 hours of continuous stirring the Sephadex was collected by 
filtration through nylon gauze. The gel was washed with 10 l 
of 10 mM sodium phosphate, 50 mM NaCl,pH 5.2 and finally 
TC II was eluted with 1500 ml of 0.2 M Tris, 1 M N~Cl pH 
8.25. The greater part of the eluted material was further 
processed for the complete purification of TC II but small 
aliquots were kept apart for the partial purification of 
TC II-[ 57co] CN-Cbl. 
2 ml CM-Sephadex eluate (binding capacity 46.5 ng CN-
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Figure 2.3. Separation of 2 ml CM-Sephadex eluate from human 
Cohn fraction III~ saturated with 18 vCi { 57 co} 
CN-Cbl, on Sephacryl S 200 Superfine. Elution 
buffer: 20 mM Sodium phosphate~ 1 M NaCl~ 0.02% 
NaN 3 ~ pH 7.4. ,Extinction at 280 nm; 57 d. . . 
o--0} Co-ra t-oact-z-v-z-ty. 
Cbl/ml and 0.57 ng CN-Cbl/mg protein) was saturated with 
18 "Ci (18 ml) [ 57co] CN-Cbl (188 "Ci/"g). After 15 min at 
room temperature the solution was concentrated by ultra-
filtration to about 4 ml and centrifuged for 30 min at 
50 000 x g. The supernatant was applied to a Sephacryl S 200 
superfine column (2.6 x 90 em). Elution took place with 
20 mM sodium phosphate, l M NaCl, 0.02% NaN 3 , pH 7.4. The 
elution profile is given in figure 2.3. The TC II-containing 
fractions were pooled and concentrated by ultrafiltration 
and meanwhile the buffer was changed to 50 mM Tris-HCl , 
pH 8.25. The concentrate waS centrifuged at 50 000 x g for 
30 min and applied to a DEAE-Sepharose CL-6B column (3 ml 
bed volume), which was equilibrated with the same Tris 
buffer. Elution took place with a concave NaCl-gradient, 
which was created by a two-pump system according to 
Lakshmanan et al. (7): a 790 mM NaCl solution in 50 mM Tris 
pH 8.25 is pumped into a mixing vessel with 200 ml Tris 
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figure 2.4. Separation of the TC II-containing fractions of 
the Sephacryl column on DEAE-sepharose CL-6B. 
Starting buffer: 50 mM Tris-HCl~ pH 8.25. The 
arrow indicates the start of the NaCl gradient~ 
which ends at about 150 mM NaCl in 50 mM Tris-
HCl~ pH 8.25. ,Extinction at 280 nm; 
57 d" . . d .. o---o) Co-ra t.-oactt.-vt.-ty; •--e,con uctt.-vt.-ty 
of the elution buffer. 
buffer at a rate of 1.18 ml per hour. The pump rate from the 
mixing vessel to the column was 15.8 ml per hour. The form 
of the salt gradient is presented in figure 2.4 together 
with the protein and radioactivity profile. The [ 57co] CN-
Cbl-containing fractions were pooled and concentrated by 
ultrafiltration and dialyzed against tissue culture medium 
(DMEM) for later incubations with isolated liver parenchymal 
cells. The specific binding activity of the purified TC II 
was 42.7 ng CN-Cbl/mg protein. 
2.4. Preparation of isolated rat liver parenchymal cells. 
Rat liver parenchymal cells were isolated by a colla-
genase perfusion procedure (8) according to Seglen (9,10). 
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Normal male Wistar rats (200-300 g) were anesthetized with 
diethylether and the abdomen was opened. The portal vein was 
cannulated with a Braunule 0.5Gl8 cannula and the liver was 
perfused in situ with approximately 400 ml calcium-free 
bicarbonate buffered Hanks' balanced salt solution (HESS) at 
37°C at a flow rate of 25 ml/min. The inferior vena cava was 
cut below the liver to allow efflux of the perfusate. A 
mixture of 5% co 2 and 95% o 2 bubbled through the perfusate 
to maintain a pH of 7.4 and optimal oxygen saturation. After 
10 min the perfusate was changed to HESS with calcium and 
0.1% collagenase (Sigma Type II). By means of a Eraunule 
1G16 cannula through the right atrium into the inferior vena 
cava and after ligation of the vena cava just below the liver 
the perfusate could be recollected and recirculated. After 
15 min the perfusion was ended and the liver, which was 
soft and leaky, was excised. By means of a sharp razor blade 
the liver was minced and incubated for another 15 min in 
fresh collagenase medium in a mildly shaking water bath. The 
cell suspension was filtered over a 63 w nylon gauze and 
washed with 100 ml of icecold HESS. The filtrate was 
collected on melting ice. The cell suspension was 
centrifuged at 50 x g for 4 min. The cell pellet was gently 
resuspended in 100 ml HESS and centrifuged again. This 
procedure was repeated twice with another 100 ml of HESS and 
once with tissue culture medium{DMEM) containing 0.09% human 
serum albumin and buffered with 25 rnM NaHco 3 at pH 7.4. The 
cells were finally resuspended in DMEM to a concentration 
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of 3.6 x 10 cells/rnl. 
This procedure consistently resulted in a cell yield 
of (450 ~ 100) x 10 6 cells (mean~ S.D., n=20) per liver. 
The viability of the isolated cells, tested by the ability 
of the cells to exclude trypan blue {0.2% in saline) was 
usually better than 95%. The integrity of the cells during 
incubations was followed by measurement of the leakage of 
the cytoplasmic enzyme lactate dehydrogenase (LDH) into the 
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medium. Before and during the incubations the enzyme 
activity in the cell free medium was determined according 
to Bergmeyer (11) and expressed as the percentage of activity 
with respect to the enzyme activity in a sonicated cell 
suspension. During the incubation a gradual increase in LDH 
activity in the medium was observed from 2.8% at zero time 
to 7.3% at 120 min (mean of 3 experiments). 
2.5. Silicon oil filtration/centrifugation technique. 
For the separation of the liver cells from the medium 
as a termination of the process of binding and uptake, 
centrifugation through silicon oil was used (12) . In this 
system 0.5 ml samples were taken from the cell suspension 
and layered on 0.6 ml silicon oil (Tegiloxan AV 100, 
Goldschmidt, Germany), which rested on 0.1 ml 10% perchloric 
acid, in a 1.5 ml micro test tube. The test tubes were 
centrifuged in an Eppendorff microcentrifuge for 1 min at 
8 000 x g. Aliquots from the cell-free supernatant were kept 
for later analysis, most of the oil was removed by suction 
and the PCA layer with the cell pellet was measured for 
radioactivity after cutting the tubes just above the 
interface between the PCA layer and the oil. 
This method has the advantage that the cells are 
completely separated from the medium and that there is no 
danger for removal of surface-bound components as with 
normal centrifugation procedures, which have to be followed 
by several washing steps. Unfortunately, the cells take 
with them a thin film of medium through the silicon oil. The 
amount of radioactivity in this film has to be subtracted 
from the total amount of radioactivity in the cell pellet 
in order to obtain the correct amount of bound and intra-
cellular radioactivity. An estimate of the amount of medium 
which is sedimentated with the cells was obtained by the 
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addition of a radioactive marker which is not bound and/or 
taken up by the cells. The distribution of radioactivity 
between the PCA layer and the medium after centrifugation 
was taken as a measure for the extracellular medium space. 
[ 3H ) inulin and [3H-methoxy ) dextran were chosen as inert 
markers. [ 3H] inulin was used in a concentration of 0.4 mM 
(1.1 ~Ci/ml). The cell suspension in DMEM with 0.09% human 
serum albumin (Behringwerke, Germany) contained 2 x 10 6 cells 
per ml. After centrifugation 50 ~1 aliquots from the PCA 
layer and 100 ~1 ~liquets from the cell free medium were 
counted for radioactivity in triton X100 - toluene 
scintillation cocktail. Duplicate samples were taken from 
two different cell suspensions at 5, 30, 60 and 120 min and 
the mean percentage of extracellular medium was determined 
to be (1.07 ~ 0.05) % (mean~ S.D.) of the 0.5 ml sample. 
There was no significant difference between the two cell 
suspensions or between the samples after different times 
of incubation. When the sample experiment was carried out 
with 25 nM [ 3H-methoxy] dextran (molecular weight 70 000), 
the mean percentage of extracellular medium was (0.97 ~ 0.05) 
% (mean ~ S.D.) . 
An even lower value was obtained when liver cells were 
incubated with the plasma cobalamin transport protein 
"cobalophilin", in particular the fraction with low iso-
electric point, also known as transcobalamin I. Vitamin B12 , 
bound to this protein, is not bound or taken up by the cells 
(see 1.2.4). Cobalophilin-[ 57co] CN-Cbl was added in a 
concentration of 500 pM and the amount of 57co-radioactivity 
in the PCA layer was found to be (0.75 ~ 0.12) %of the 
total radioactivity in the sample (mean~ S.D., n=l3). 
With these extracellular markers, three slightly 
different values for the extracellular space in the PCA 
layer are found. Although the experiments with the cobalo-
philin possibly give the best imitation of the incubations 
with TC II, the better reproducibility of the methoxydextran 
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experiments has made us choose the value obtained with this 
marker. 
The correct values for binding and uptake of TC II-
vitamin B12 by the liver cells in suspension are obtained 
by subtraction of 0.97% of the radioactivity in the 0.5 ml 
samples from the total radioactivity in the cell pellet. All 
data for binding and uptake by liver cells in the chapters 
4 and 6 have been corrected this way. 
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chapter 3 
BINDING SITES FOR TRANSCOBALAMIN ll-VITAMIN Bn ON ISOLATED RAT LIVER PLASMA 
MEMBRANES 
3.1. Summary. 
Binding sites for transcobalamin II-vitamin B12 complex 
from rat plasma were localised on isolated rat liver plasma 
membranes. The saturable binding process had an apparent 
affinity constant of 8.6 x 10 9 M- 1 . The specific binding 
capacity of the plasma membranes was 1.5 x 10 10 binding 
sites per mg membrane protein. No competitive inhibition 
was observed with free vitamin B12 or unsaturated trans-
cobalamin II. A large part of the binding activity could 
be detached from the membrane either by incubation in 
detergent solution or by incubation in the presence of 
trypsin, whereas several other hydrolytic enzymes were 
found to be ineffective in this respect. The binding 
affinity of the plasma membranes prepared from other organs 
was of the same order of magnitude as the affinity of the 
binding sites from the liver. 
3.2. Introduction. 
The high association constant of vitamin B12 for its 
plasma transport protein, transcobalamin II (TC II), 
2 x 10 11 M- 1 at body temperature (1), and the consequently 
low concentration of free vitamin B12 in the blood plasma, 
make it very unlikely that vitamin B12 enters the tissue 
cells in the free form. Transcobalamin II is thought to be 
a mediator in the process of uptake by the cells (2,3). 
This was confirmed by the observations on patients with 
congenital deficiency of TC II, who are unable to utilize 
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physiological amounts of vitamin B12 (4). The studies of 
Pletsch and Coffey (5) demonstrated that in vivo the TC !!-
vitamin B12 complex.binds to the surface membrane of the rat 
liver cells prior to the cellular uptake. This uptake is 
presumably mediated by pinocytosis, because the distribution 
of the vitamin B12 molecules over the different cell compart-
ments showed a shift sequentially from plasma membranes to 
microsomal vesicles, lysosomes and finally mitochondria. The 
binding of TC !!-vitamin B12 to the plasma membrane suggests 
the presence of specific binding sites for TC II-vitamin B12 . 
Such binding sites have been described earlier by Fiedler-
Nagy et al. (6). In this chapt.er these observations are 
partially confirmed, and extended with data on the 
characteristics of the binding process. 
3.3. Methods. 
3.3.1. Partial purification of transcobalamin II-vitamin B12 
Transcobalamin II- ( 57 co] CN-Cbl was purified from 
normal rat serum as described in 2.3.1 but an additional 
purification step was included, namely precipitation of the 
serum with 60% (NH 4 ) 2so4 , after saturation with [
57co] CN-
Cbl. The precipitated protein was dissolved in 20 mM Tris-
HCl pH 7.4 and further purified on Sephadex G 150 as 
described in 2.3.1. The final purification factor was 
increased to 300 times by pOoling only the right part of 
the TC II peak in the Sephadex G 150 eluate. The specific 
binding activity amounted to 11.7 ~g CN-Cbl/mg protein. 
The pooled material was concentrated by ultrafiltration 
and dialysed against 20 mM Tris-HCl, 0.15 M NaCl pH 7.4. 
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After exsanguination of the rats (200-250 g) by heart 
puncture the livers were removed, homogenized and centrifuged 
according to Neville (7) as modified by Ray (8), with the 
exception that the final density gradient purification step 
was performed in a Sorvall SZ-14 reorienting zonal rotor 
according to Evans (9). The zonal rotor was dynamically 
loaded with solutions of sucrose in 1 rnM NaHC0 3 , 0.5 mM 
cacl 2 , pH 7.4 in the following order: 100 ml of 45%, a 
linear gradient of 600 ml from 45% to 31%, a linear gradient 
of 200 ml from 31% to 22.5%, 100 ml of 22.5% and 200 ml of 
8% sucrose (w/w). The linear gradients were generated with 
a Sorvall GF-2 gradient maker. The sample was introduced in 
a volume of 25 ml and centrifugation was carried out at 
4 000 rpm for 50 min at 5°C. At the end of the run the rotor 
was emptied statically by pumping the gradient from the 
bottom of the rotor, while the effluent was monitored for 
protein at 280 nm. 12 ml fractions were collected and the 
sucrose concentration of the fractions was determined by 
measurement of the refractive index. 
The fractions rich in plasma membrane marker enzyme, 
5'-nucleotidase, and poor in mitochondrial marker enzyme, 
succinate dehydrogenase, were pooled, diluted with one 
volume of 1 mM NaHC0 3 , 0.5 rnM cac12 , pH 7.4 and collected 
by centrifugation for 30 min at 17 000 x g. The membranes 
were washed twice with bicarbonate, calciumchloride solution 
and finally resuspended to a concentration of 5 mg/ml. The 
purity of the isolated membranes was determined by measure-
ment of the activities of 5'-nucleotidase succinate dehydro-
genase, the lysosomal marker s-glucuronidase and of protein. 
Table 3.1 summarizes these analytical data, which are 
generally in agreement with data in the litera~ure (8,9) 
5'-nucleotidase was measured according to Persyn et· al. 
(10), succinate dehydrogenase as described by King (11) and 
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S-glucuronidase by the method of Levvy et al. (12). Protein 
was measured according to Lowry et al. (13) with bovine serum 
albumin as a standard. 
Binding studies were carried out at room temperature 
unless indicated otherwise. The standard incubation mixture 
contained a varying amount of rat TC rr-[ 57co] CN-Cbl, 
14 7 "f.! moles NaCl, 4 "f.! moles KCl, 5 ~moles CaCl 2 , 10 ).!mOles 
Tris-HCl, pH 7.2 and 0.5 mg of membrane protein in a volume 
of 1 ml. After the incubation, generally for 30 min, the 
mixtures were diluted with 3 ml of ice-cold 1 roN NaHC0 3 , 
0.5 mM Cacl 2 , pH 7.4, collected by centrifugation for 10 min 
at 3 500 x g at 4°C and washed twice with the same solution. 
The radioactivity in the pellet was measured and 
[57 J [57co] calculated as pmoles Co CN-Cbl by comparison with 
CN-Cbl standard solutions of known specific activity. All 
incubations were carried out in duplicate and correction for 
non-specific binding to the assay materials was obtained by 
incubations without plasma membrane material. 
3.4. Results. 
----
An initial experiment was carried out to demonstrate 
that TC rr-[ 57co]cN-Cbl binds exclusively to the plasma 
membrane. An unfractionated 1 000 x g sediment from rat 
liver homogenate was incubated in a standard incubation 
mixture with TC rr-[ 57co)cN-Cbl and separated in a zonal 
sucrose density gradient as described in 3.3.2. The separate 
fractions were analysed for radioactivity, sucrose density, 
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fig. ~.1. Distribution pattern after sucrose density gradient 
centrifugation of a 1 000 x g sediment from rat 
li~er homogenate~ ~hich was preincubated with 
partially purified TC II-{57 co}CN-Cbl. 
5'-nucleotidase and succinate dehydrogenase activity. As 
demonstrated in figure 3.1 the ( 57co]cN-Cbl radioactivity 
and 5'-nucleotidase activity coincided at sucrose concentra-
tions from 37-41%. Peak activities were located at 39% 
sucrose, which has been formerly shown to correlate with the 
density of plasma membranes (8). These data confirm that 
binding sites for the TC II-vitamin B12 complex are present 
on the rat liver plasma membranes. 
An~Zytic data of plasma membrane preparations. 
assay result as a mean of 3 experiments 
milligrams of protein per g 
liver, wet weight 
5'-nucleotidase 
succinate dehydrogenase 
B-glucuronidase 
recovery based on 5'-nucleotidase 
enrichment based on 5'-nucleotidase 
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fig. 3.2. Binding of TC II-{ 57 co}cN-Cbl to plasma membranes 
as a function of TC II-CN-Cbl concentration. 0.5 
mg of membrane protein was incubated in the 
standard incubation mixture for 30 min at 25°C at 
different TC II-{57 co}cN-Cbl concentrations. 
Insert: Scatchard plot of the experimental data. 
The intercept on the abscissa represents the 
maximal amount of TC II-{57 co}cN-Cbl bound or of 
available bincling sites, whereas the slope of the 
curve stands for the apparent affinity constant. 
3.4.2. Binding of transcobalamin II-vitamin B12 to isolated 
£l~s~a=m~~r~n~s~ - - - - - - - - - - - - - - - - -
In 5 separate experiments, in which plasma membrane 
fractions from different liver homogenates were used, the 
membrane binding capacity for TC II-vitarnin B12 was studied 
as a function of the concentration of TC II-vitarnin B12 . The 
binding was saturable and an estimate of the apparent 
affinity constant was made using Scatchard analysis, in 
which the "bound to free" ratio is plotted versus the 
amount of TC rr-[ 57co]CN-Cbl bound (figure 3.2. + insert) 
The affinity constant, represented by the slope of the line, 
ranged from 5 to 12 x 10 9 M- 1 with a mean of 8.6 x 10 9 M- 1 
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fig. 3.3. The influence of free CN-Cbl~ unsaturated and 
CN-Cbl-saturated plasma on the binding of TC II-
[57 Co} CN-Cbl to plasma membranes. The conditions 
were the same as in fig. 3. 2. 0-- o, standard 
incubation; x--x,with 0.2 pmoZes CN-Cbl; 
•--e,with 0. 2 mZ unsaturated plasma and 
o--o,with 0. 2 ml saturated plasma. 
{n=S). The specific number of binding sites was calculated 
from the intersections on the abscissa of the Scatchard plot 
10 10 
and ranged from 0.6 to 3.7 x 10 (mean 1.5 x 10 ) per rng of 
membrane protein. The specificity of the binding process 
with respect to free CN-Cbl and saturated or unsaturated 
binding protein is illustrated in figure 3.3. Scatchard 
analysis of the binding in the presence of free CN-Cbl or 
unsaturated rat plasma indicated that no competition between 
the labeled saturated binder and the free vitamin or 
unsaturated TC II took place in contrast with unlabeled 
saturated TC II, which reduced the affinity for TC rr-[ 57co] 
CN-Cbl. These data suggest that the plasma membrane binding 
sites have a clear preference for saturated TC II in 
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Fig. 3.4. pH dependence of the binding process. The 
incubation medium contained 50 mM Tris-maleate 
buffer, 4 mM CaCl 2 , 0. 07 pmoles TC II-[
57 Co} CN-Cbl 
and 0.6 mg of plasma membrane protein in 1 ml. 
comparison to free CN-Cbl and unsaturated binding protein 
in the conditions used in our experiments. 
The binding of free [ 57 co) CN-Cbl to the isolated 
membranes was about 8% of the binding of the TC II-CN-Cbl 
complex, which agrees well with the findings of Fiedler-Nagy 
etal. (6). 
The binding of TC rr-cN-Cbl to liver plasma membranes 
was not influenced by the presence or absence of calcium 
ions. Addition of EDTA (2.5 rnM) instead of calcium caused 
in different membrane preparations, a variable increase in 
the maximal amount of bound TC II-CN-Cbl, without affecting 
the affinity constant. The highest number of binding sites, 
10 
observed in the presence of EDTA, was 6.6 x 10 per mg of 
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Fig. 3.5. Time and temperature dependence of the binding 
process. 0.3 mg of membrane protein was incubated 
in the standard incubation medium with 0.0? pmoles 
TC II-{57 Co} CN-Cbl per ml at three different 
temperatures. 
membrane protein. 
The pH dependence of the binding process is shown in 
figure 3.4. Naximal binding occurred at pH 5.5 and a steady 
decrease took place to a minimum at pH 9.0. 
An analysis of the tirr,e dependence of the binding 
process is given in figure 3.5. Although the rate at which 
equilibrium was reached, increased with temperature, the 
level of the plateau was the same at all temperatures and 
was maintained for at least 30 min. 
Isolated plasma membranes were treated with several 
hydrolytic enzymes or detergents, washed thoroughly and 
incubated ;,vith TC rr-[ 57co] CN-Cbl to measure the effects 
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Table 3.2. Effect of enzyme incubations~ detergents and 
SH-reagents on the binding of TC II-{ 57 Co} CN-Cbl 
by liver plasma membranes. 
treatment/additive 
none 
neuraminidase 
lipase 
mannosidase 
s-galactosidase 
trypsin 
phospholipase A 
triton X-100 
sodium deoxycholate 
dithiothreitol 
2-rnercaptoethanol 
concentration 
0,25 mg/ml 
0,50 mg/ml 
0,25 mg/ml 
0,25 mg/ml 
0,50 mg/ml 
0,50 mg/ml 
1 % 
1 % 
2,5 mM 
2,5 mM 
percentage of 
control bound 
100 % 
110 % 
97 % 
100 % 
100 % 
30 % 
95 % 
40 % 
35 % 
98 % 
100 % 
Membrane material was preincubated with the enzymes for 
60 min at 37°C in 0.15 M NaCl or~ with neuraminidase~ in 
0.2 M sodium acetate buffer pH 5.6~ washed two times with 
1 mM NaHCO 3 , 0. 5 mM Cacl 2 ~ pH 7. 4 and suspended in the same 
volume as the control. The same procedure was followed in 
case the membranes were incubated with detergents. The 
standard incubation mixture contained 0.6 mg of membrane 
protein and 0.1 pmole of rat TC II-{57 Co} CN-Cbl per ml. 
The effects of dithiothreitol and 2-mercaptoethanol were 
studied in the standard incubation mixture. The enzymes 
were purchased from Boehringer (Mannheim~ Germany). 
of the pretreatment on the binding process. The results are 
given in table 3.2. 
Only trypsin and the two detergents reduced the amount of 
bound radioactivity significantly. Incubations with different 
TC rr-[ 57co] CN-Cbl concentrations showed that the reduction 
in binding was not due to a decrease in binding affinity but 
to a reduction in the number of binding sites. 
2-mercaptoethanol and dithiothreitol did not influence 
the binding when present in the standard incubation mixture. 
This suggests that for the binding mechanism intact disulfide 
bridges are not essential. 
Plasma membrane-rich 1 000 x g subtractions of homo-
genates from heart, liver, brain, kidney and spleen were 
prepared and the binding affinity for TC II-CN-Cbl was 
studied. The respective affinity constants, obtained by 
Scatchard analysis, are presented in table 3.3. 
Table 3.3. Binding affinity of plasma membrane-rich fractions 
from various rat tissues. 
tissue affinity constant 
liver 4.5 X 10 9 M-1 
heart 4. 0 X 10 9 M-1 
brain 4. 7 X 10 9 M-1 
kidney 3.7 X 10 9 M-1 
spleen 4 .o X 10 9 M-1 
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3.5. Discussion. 
Our studies demonstrate the presence of binding sites 
for transcobalamin II~CN-Cbl on the plasma membranes of rat 
liver cells. This finding confirms the assumption of the 
presence of such binding sites, made by other investigators 
on the basis of vitamin B12 transport studies in intact 
animals and cell suspensions (5,14). In our studies the 
plasma membrane fraction was prepared from a low centrifugal 
force pellet from a rat liver homogenate according to Evans 
et al. (9). 
Fiedler-Nagy et al.(6), who isolated membranes from 
a microsomal pellet, studied the membrane affinity towards 
TC II-vitamin B12 in unfractionated plasma. Our data are in 
agreement with their results regarding the affinity constant 
of the binding 1 but our calculation of the number of specific 
binding sites is somewhat lower. A major difference with the 
studies of Fiedler-Nagy et al. {6) concerns their finding 
that plasmal not saturated with vitamin B12 , inhibited the 
uptake of radioactive vitamin B12 bound to transcobalamin. 
On the contrary, in the present study no inhibition of the 
binding by free CN-Cbl or unsaturated plasma was found, 
which may be explained by the fact that plasma and the TC II-
( 57 co] CN-Cbl were added at the same time, whereas Fiedler-
Nagy et al. {6) pre-incubated the plasma membrane with the 
unsaturated plasma. Physiologically it seems unlikely that 
unsaturated TC II competes with TC II-CN-Cbl for the 
binding sites on the cell membrane, because in vivo the 
higher level of unsaturated TC II in blood plasma would 
prevent the attachment of saturated TC II to the binding 
sites and the subsequent uptake into the cells. 
Accordingly 1 Hall has reported recently that Hela cells 
and human lymphocytes showed a preferential uptake of 
saturated TC II, which was not affected by a 6-fold excess 
of saturated binder {15). 
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The pH optimum of 5.5 for rat liver membranes is the 
same as for the primary uptake of TC II-vitamin B12 by mouse 
leukemia cells (14). Liver membranes, remarkably, do not 
require the presence of Ca++ for the binding process and 
EDTA even seems to render more binding sites accessible for 
the TC II-vitamin B12 complex. On the contrary the binding 
and uptake by several other cell types (2,3,14 1 16) is 
strongly inhibited by EDTA. These observations suggest that 
the liver membrane binding sites differ from the binding 
sites on other cells. 
In an attempt to define the nature of the membrane 
binding sites by treatment of the purified membranes with 
several hydrolytic enzymes 1 and measurement of the effect 
on the binding activity, only trypsin proved to reduce the 
number, but not the affinity, of the binding sites. One may 
conclude from this, that at least a part of the binding site 
contains protein. Sialic acid does not seem to be directly 
involved because neuraminidase had no effect on the binding 
process. Lipolytic enzymes also did not interfere with the 
binding activities of the membranes in our experiments. 
The results of this study demonstrate, that a protein-
containing compound from liver plasma membrane specifically 
binds TC II-vitamin B12 probably as a primary step in the 
uptake mechanism. Data from kidney and liver uptake of TC !!-
vitamin B12 suggest that after a pinocytotic process the 
complex moves into the lysosomal system, where it is 
probably degraded and the vitamin released from its binding 
protein (5,17,18). If the binding sites are localized on 
those parts of the membrane \-7hich are subject to pinocytosis, 
a continuous flow of TC !!-vitamin B12 into the cell can be 
expected, also in view of the affinity constant, which 
indicates that at a normal TC II-vitamin B12 concentration 
in the plasma of about 500 pM, most binding sites will be 
occupied by TC II-vitamin B12 . 
The binding affinities of membrane preparations from 
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different rat tissues are all of the same order of magnitude. 
This indicates that possible differences in the rate of 
uptake are likely to be the result of differences in the 
number of receptor sites on the membrane or in the velocity 
with which the pinocytotic process transports the complex 
into the cell. 
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chapter 4 
BINDING, UPTAKE AND RELEASE OF TRANSCOBALAMIN II- [s7co] CYANOCOBALAMIN BY 
ISOLATED RAT LIVER PARENCHYMAL CELLS 
4. 1. Summary. 
Isolated rat liver parenchymal cells were incubated 
with partially purified rat or human TC II-vitamin B12 , which 
was radioactively labeled in the vitamin moiety. A rapid 
binding onto the surface of the cells in the first few 
minutes was followed by a steady linear increase of intra-
cellular ( 57 co] CN-Cbl in the next hour. With increasing 
concentrations of TC II the uptake became partially 
saturated and apparently TC II-Cbl is taken by two processes, 
a saturable specific uptake and a non-saturable non-specific 
uptake. The former process is probably due to specific 
binding sites on the plasma membrane. In contrast to 
observations on other cells, the process of binding and 
uptake was independent of calcium and could not be inhibited 
by EDTA or EGTA. Chloroquine, a lysosomotropic agent, caused 
an accumulation of intracellular Cbl, presumably by 
inhibition of intralysosomal proteolysis of the transport 
protein. It was concluded first, that TC II-vitamin B12 is 
taken up by a mechanism of adsorptive endocytosis, followed 
by fusion with the lysosomes, and second that normally the 
cells secrete most of the internalized vitamin shortly after 
the uptake. This was confirmed by the observation that 30-
100% of radioactive vitamin B12 , which had been taken up 
shortly before the isolation of the liver cells 1 was 
released again in two hours of incubation. 
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4.2. Introduction. 
In chapter 3 the binding of the TC II-vitamin B12 
complex to isolated plasma membranes has been described and 
it was concluded that the first step in the entrance of 
vitamin B12 into the cell is the binding of TC II-vitamin 
B12 to specific binding sites on the plasma membrane. The 
progress of the uptake mechanism, however, remains to be 
studied. Several mechanisms are possible: the carrier protein 
stays behind while the vitamin is transported through the 
membrane into the cell, or the whole complex enters the 
cytoplasm through the membrane or the complex enters the 
cell engulfed in pinocytotic vesicles (1). 
As a logical sequel to the liver plasma membrane 
experiments the isolated liver cell was chosen as an in 
vitro system to study the uptake of vitamin B12 by the cell. 
Liver parenchymal cells are rather easy to isolate, can be 
maintained in suspension in a relatively normal, viable 
state (2) and have been used previously for the investiga-
tions of the uptake and degradation of rat high-density 
lipoprotein (3) and asialoglycoprotein (4). 
In this chapter the results of experiments are presented 
in which the vitamin moiety is radioactively labeled. Some 
of the experiments were carried out with human transcobalamin 
II and some with rat TC II for practical reasons and also to 
establish that there was no fundamental difference in the 
uptake of vitamin B12 , whether it was bound to human or to 
rat TC II. 
4.3. Methods. 
Liver parenchymal cells were isolated as described in 
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section 2.4. The cells were washed and finally suspended in 
Dulbecco's modified Minimal Essential Medium (DMEM) in a 
concentration of 3.6 x 10 6 cells/ml. All glassware was 
siliconized in 1% siliclad (Clay-Adams), rinsed with 
distilled water and dried. 
TC rr-[57co] CN-Cbl was partially purified as described 
in section 2.3.1. The final preparation was dialyzed against 
2 x 1 L DMEM for 48 hours and centrifuged at 100 000 x g for 
1 hour. All necessary dilutions were made in DMEM with 
0.09% human serum albumin and buffered at pH 7.4 with 25 mM 
NaHC0 3 . 
7 ml aliquots of a cell suspension were distributed 
over 25 ml Erlenmeyer flasks and kept on melting ice. Just 
before the incubation the flasks were preincubated in a 
shaking waterbath at 37° for 5 min. The incubation was 
started by the transfer of 5 ml cell suspension to another 
25 ml Erlenmeyer, which contained TC rr-( 57co] CN-Cbl and 
eventually other additives in a volume of 4 ml. These latter 
flasks were also preincubated at 37°C. The Erlenmeyers were 
placed in a shaking waterbath and gassed with 95% o 2 , 5% C0 2 . 
At various time intervals 0.5 ml duplicate samples were 
taken and the cells were separated from the medium with the 
silicon oil filtration-centrifugation technique described 
in section 2.5. The cellular uptake was corrected for 
adherent waterspace as outlined in the same section and 
9 
expressed as prnoles/10 cells. 
To avoid contact of the cells with too high concentra-
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tions of the agents, EDTA, EGTA were added in a concentration 
which gave an excess of 1 mM over the concentration of biva-
lent cations in the medium. This excess was checked by 
complexometric titration with eriochrome black T. It was 
taken care off that the normal pH of the medium was 
maintained after the sequestration of the cations. 
4.4. Results. 
4.4.1. ~eEegd~n£e_of ~i~d~n~ and ~p!ake ~n_cQn£e~t£atio~ of 
!C_II-l5~c~ lc~-£bl. 
Binding and uptake of rat TC II-[ 57co) CN-Cbl by the 
isolated liver parenchymal cells showed a rapid rise in the 
first 5 min and a steady linear increase in the next hour. 
(fig. 4.1.). The first phase is thought to represent the 
adherence of the protein to the binding sites on the plasma 
membrane and the second phase probably represents the 
entrance of the complex into the cells. Rat TC II and human 
TC II (figure 4.2) showed corresponding patterns, but human 
TC II seemed to be bound and taken up in somewhat higher 
amounts. The amount of initial binding and the rate of 
uptake were dependent on the extracellular concentration of 
TC II. 
The initial binding was defined as the intercept on the 
ordinate 1 which is obtained by extrapolation of the time 
dependent uptake curve to time zero. In figure 4.3 the 
binding of rat TC II-[ 57co] vitamin B12 is plotted as a 
function of the concentration and figure 4.4 shows the rate 
of uptake, represented by the slope of the time dependent 
uptake curve from 5 to 60 min 1 as a function of the 
concentration. Both curves do not seem to reach saturation 
but the profile of the curves suggests that the measured 
binding and uptake are the sum of a saturable and a non-
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fig. 4.1. Time course of the binding and uptake of rat TC II-
{57 Co} CN-Cbl by rat liver parenchymal cells at 
four concentrations: e--e,?O pM; o--0,200 pM; 
~--v,400 pM and o---o,680 pM TC II-[ 57 Co}CN-Cbl. 
Each point is the mean of duplicate measurements. 
saturable component. 
The saturable component is probably the result of 
binding of TC IT-vitamin B12 to the specific binding sites 
on the plasma membrane, whereas the non-saturable uptake 
is probably caused by non-specific binding to the cell 
membrane. 
With human TC rr-[ 57co] CN-Cbl we were able to analyse 
this non-specific binding and uptake by incubations in the 
presence of 10 nM excess unlabeled human TC II-CN-Cbl. At 
this high concentration and consequently low specific 
radioactivity of the TC II-CN-Cbl the measured specific 
binding and uptake of [57co] vitamin B12 is negligible in 
relation to the total binding and uptake. The observed rise 
in cellular radioactivity with time was therefore assumed 
to represent largely non-saturable and non-specific uptake. 
The non-specific binding of human TC Ir-[ 57co] CN-Cbl 
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fig. 4.2. Time course of the binding and uptake of human 
TC II-{57 Co} CN-Cbl by rat liver parenchymal cells 
at four concentrations: e--e,95 pM; •--a,191 pM~· 
v--v,395 pM and D--o,615 pM TC II-( 57 co} CN-Cbl. 
Each point is the mean of duplicate measurements. 
in the presence of 10 nM TC II-CN-Cbl was a linear function 
of the concentration of TC rr-[ 57co] CN-Cbl. The specific 
binding was calculated by subtraction of the non-specific 
binding from the partially saturable total binding observed 
in the absence of unlabeled TC II-CN-Cbl. The specific 
binding plotted as a function of the concentration (figure 
9 4.5) was saturable and had an affinity constant of 6.9 x 10 
-1 M , calculated by Scatchard analysis. 
A similar procedure was followed for the kinetic 
analysis of the rate of uptake as a function of the 
concentration. The rates of uptake at each concentration of 
TC Ir-[ 57 co] CN-Cbl in the presence of 10 nM unlabeled TC II-
CN-Cbl were subtracted from the rates of uptake at the same 
concentrations without unlabeled TC LI-CN-Cbl. The rate 
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fig. 4.3. Binding of [ 57 co}cN-Cbl to liver 
cells as a function of the rat TC 
parenchymal 
II-[57 Co j CN-Cbl 
1.0 
0.5 
concentration. Each point represents the amount of 
cell associated radioactivity at time zero~ obtained 
by extrapolation of the linear part of the curves 
in figure 4.1~ at the indicated concentration. 
pmoles/109 cells/hour 
• 
0 
• • 
200 400 600 800 
TCII-[57 Co] CN-Cbl (pmoles/1) 
Fig. 4.4. Rates of uptake of [ 57 co }cN-Cbl as a function of 
the rat TC II concentration. Each point represents 
the mean rate of uptake from 5 to 60 min at the 
indicated concentration. 
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fig. 4.5. Specific binding of{ 57 co}cN-Cbl to liver 
parenchymal cells as a function of the human TC II-
{57 Co} CN-Cbl concentration. Each point is obtained 
by subtraction of the non-specific binding of { 57 co} 
CN-Cb l from the total binding of { 57 Co} CN-Cb l at 
the indicated concentration. The insert represents 
the Scatchard plot of the same experimental data. 
of non-specific uptake was a linear function of the 
concentration but the calculated rate of specific uptake 
was saturated at about 400 pM and reached a maximal value 
of 1.1 pmoles/10 9 cells/hour (figure 4.6). Half-maximal rate 
of specific uptake was reached at about 140 pM which is close 
to the concentration at which half-maximum binding occurred, 
namely 145 pM. 
The effect of EDTA and EGTA on the binding and uptake 
was studied at 100 and 600 pM of TC rr-[ 57co] CN-Cbl. At 
both concentrations binding and uptake were equal to the 
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fig. 4.6. Rates of uptake of{ 57 co}CN-Cbl as a function of 
the human TC II-{57 Co} CN-Cbl concentration. Each 
point represents the mean rate of uptake from 5 to 
60 min at the indicated concentration. e e, 
incubation with TC II-{57 Co} CN-Cbl alone; o---o, 
incubation with TC II-{57 Co} CN-Cbl in the presence 
of 10 nM pure human TC II-CN-Cbl; ----,course of 
the rate of specific uptake~ obtained by subtraction 
of the lower curve from the top curve. 
control incubations during the first 30 min. After this time 
the liver cells tended to agglutinate in the presence of the 
chelators, which resulted sometimes in large differences in 
the duplicate measurements. However, the conclusion seems to 
be justified that the binding and uptake of TC II by liver 
parenchymal cells are calcium and/or magnesium independent. 
This is in agreement with the observations on the binding 
of TC II-Cbl to isolated liver plasma membranes which was 
also no inhibited by the addition of EDTA or EGTA (chapter 3). 
pmole> [57 Co] CN-Cbl 
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fig. 4. 7. Effect of chloroquine on the binding and uptake 
of human TC II-{57 Co} CN-Cbl. v--v,control cells, 
incubated with 400 pM TC II-{57 Co j CN-CbZ. 
L'.--n,cells incubated with 400 pM TC II-[57 co} 
CN-CbZ and 3.5 mM chloroquine. 
4.4.3. ~f!e£t_of £hlo~ogu~n~ ~n_t~e_u£t~k~ of TC !I=l5~c~]_ 
CN-Cbl. 
The data in section 4.4.1 indicated that TC II-CN-Cbl 
is bound to the cell membrane and subsequently is taken up 
by the cells. It was, however, uncertain whether the measured 
uptake represented the total uptake by the cells or whether 
it was the resultant of an uptake and a release process in 
which the uptake was somewhat larger than the release. The 
latter concept was supported by the results of an experiment 
in which chloroquine was added to the incubation medium. 
This lysosomotropic agent, an inhibitor of lysosomal 
proteolysis, caused an almost threefold increase of the 
cellular uptake without affecting the initial binding of 
TC II-CN-Cbl to the cell membrane. (figure 4.7). Vitamin B12 
apparently accumulates in the lysosomes as a result of the 
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inhibition of the proteolytic degradation of TC II. This 
observation also indicates that in the absence of chloroquine 
the real rate of uptake is higher than the observed rate of 
uptake and that a part of the internalized vitamin B12 is 
released by the cells shortly after the uptake. 
The data from the experiments with chloroquine suggest 
that Cbl is released from the cells shortly after the uptake. 
In order to measure this release, experiments were carried 
out, in which the liver cells were loaded with radioactively 
labeled vitamin B12 by the intravenous injection of [
57
co) 
CN-Cbl, prior to the isolation procedure. After isolation of 
the parenchymal cells the release of the radioactive label 
was measured during incubations under standard conditions. 
When the injection of [ 57 Co ] CN-Cbl took place 30' 
before the start of the liver cell isolation, a substantial 
part of the radioactive vitamin B12 was released into the 
medium (figure 4.8). The initial release became larger 
with increasing extracellular TC II concentrations, but the 
subsequent releases were apparently not influenced by the 
extracellular TC II concentrations. Without extracellular 
TC II about 15% of the cellular radioactivity was released 
within the first minute but at 280 pM TC II almost 50% could 
be recovered instantaniously in the medium. At this high 
concentration of TC II the total cellular content of [ 57co) 
Cbl was released in two hours.At o 0 c some initial release 
occurred but no further loss of radioactivity was detectable 
in the following two hours. 
In contrast with the release of recently internalized 
radioactive Cbl, the total release of endogenous vitamin B12 , 
measured with the radioassay, increased linearly and 
independently of the extracellular concentration of TC II, 
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fig. 4.8. Release of { 57 co}cN-Cbl and unlabeled Cbl from 
isolated liver cells~ expressed as percentage of 
the initial cellular amount of { 57 Co} CN-Cbl and 
Cbl. The cells were loaded with radioactive 
vitamin B 12 by an intravenous injection of 1 ~Ci 
{ 57 Co} CN-Cbl 30 min before the isolation of the 
parenchymal cells. The loaded cells were incubated 
under standard conditions with partially purified 
rat TC II-CN-Cbl in concentrations ranging from 
0 to 280 pM. The solid lines represent the release 
of [ 57 Co} CN-Cbl at the various concentrations of 
unlabeled TC II-Cbl and each point is the mean of 
duplicate measurements. The broken lines represent 
the release of total unlabeled Cbl and each point 
represents the mean value + S.D. of the incubations 
at all different TC II-Cbl concentrations. In 
addition the release of Cbl and { 57 Co} CN-Cbl tJas 
measured at 0°C: x---x,release of { 57 Co} CN-Cbl; 
x------x,release of total unlabeled Cbl. 
(figure 4.8 broken lines). It reached only 15% of the amount 
of total initial intracellular vitamin B12 content. At 0°C 
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release of endogenous vitamin B12 was absent. It is possible 
that a part of the released vitamin originated from cells 
which became leaky during the incubation, but comparison 
with the activity of the cytoplasmic marker enzyme LDH in 
the medium showed that the percentage of release of vitamin B12 
was at least two times higher than the percentage of release 
of the enzyme (see section 2.4). Therefore part of the 
observed vitamin B12 release was explained as an active 
release from the cells. 
When radioactive vitamin B12 was injected 70 hours 
before the onset of the liver cell isolation, the initial 
( 57co] vitamin B12 release was negligible at all extracellu-
lar concentrations of TC II-CN-Cbl and also the further 
release was independent of the extracellular TC II 
concentration. The release was linear and reached only 18.6% 
of the cellular radioactivity after 2 hours of incubation. 
The release of total endogenous vitamin B12 in this experi-
ment was 19.3% after 2 hours of incubation and it can be 
concluded that after 70 hours the radioactive vitamin B 12 
has been taken up in the stable pool of endogenous vitamin 
B 12 and therefore is released in the same way as the 
unlabeled vitamin in this pool. 
4.4.5. Measurement of the excretion of vitamin B12 into the 
biTe-: 
In the preceding section it was demonstrated that 
vitamin B12 is released from the liver parenchymal cells 
at a relatively fast rate with respect to vitamin B12 in a 
pool of recently internalized vitamin, and at a proportional-
ly slower rate for the large cellular pool. This release may 
have occurred at the circulatory and/or the biliary side of 
the liver cell. 
In order to investigate the direction of the release 
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fig. 4.9. Accumulated radioactivity in the bile in two 
different rats after the intravenous administration 
of 1 "Ci [ 57 Co} C/1-CbZ. 
of vitamin B12 , rats were intravenously injected with [
57
co] 
CN-Cbl after insertion of a cannula into the bile duct. Bile 
secretion remained 
57 d. . . Co-ra loactlVlty 
constant at a flow of 0.3 to 0.4 ml/hour. 
in the bile appeared shortly after the 
injection and increased linearly during about 3 hours 
(figure 4.9). The amount of radioactivity excreted after two 
hours was 2-3% of the total liver radioactivity at that 
moment. The total amount of vitamin B12 in the bile was 
2.3 ng/ml, which is less than 0.1% per hour in relation to 
the total liver vitamin B 12 pool. The vitamin B12 in the 
bile was in the free form as was established by Sephadex GSO 
column chromatography. 
4.5. Discussion. 
The uptake of TC !!-vitamin B12 by isolated liver cells 
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has three aspects: the binding of the complex to the 
specific binding sites on the plasma membrane, the transport 
into the cell, and the intracellular processing of the 
vitamin and the transport protein. 
The biphasic profile of the time dependent increase in 
cell bound radioactivity suggests that the binding of TC II-
Cbl to the surface of the cell predominates in the first 
phase of rapid rise in cell-associated radioactivity and 
that the further increase is the result of the entrance of 
the complex into the cell. It is difficult to measure binding 
and uptake separately and therefore the amount of binding at 
each concentration of TC II was estimated by extrapolation 
of the linear part of the curve, representing the increase 
of intracellular TC II-Cbl, to time zero. 
The binding and uptake of human and rat TC II-Cbl by 
the liver cell were both partially saturable. It was assumed 
that a part of the process was non-specific and the size of 
the non-specific component was estimated by incubations in 
the presence of 10 nM unlabeled pure human TC II-CN-Cbl. The 
non-specific binding and uptake were a linear function of 
the concentration of TC II-[ 57co] CN-Cbl. The specific binding 
and uptake were calculated by subtraction of the non-specific 
binding and uptake from the total binding and uptake and 
were found to be saturable at concentrations above 400 pM. 
These results are in agreement with the observations of 
Youngdahl-Turner et al. (5) on the specificity of the binding 
of TC II-Cbl to fibroblasts in culture. The observed affinity 
constant for the binding of TC II-vitamin B12 by the liver 
cell is in agreement with the affinity constant which was 
found with the isolated liver plasma membranes. The similarity 
between the concentration dependent curves for binding and 
uptake suggests that the rate of uptake is primarily deter-
mined by the degree of occupation of the specific binding 
sites. Further studies are necessary to find out to what 
extent the non-specific binding and uptake are physiological 
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phenomena or features of this particular liver cell system. 
The observation that the binding and uptake of TC II by 
the liver cell is independent of calcium, confirms our 
results obtained with the bindjng of TC II to isolated liver 
plasma membranes and is also in agreement with the studies 
of Fiedler-Nagy et al. (6). 
The accumulation of 57co-radioactivity in the cell as 
a result of the presence of chloroquine is explained by the 
fact that this lysosomotropic agent is an inhibitor of 
lysosomal proteolysis (7,8). Apparently TC II-vitamin B12 is 
transported to the lysosornes, where in the absence of 
chloroquine the protein is degraded and the vitamin B12 
molecule is dissociated from its transport protein. A 
blockade of lysosomal proteolysis by chloroquine apparently 
prevents the bound cobalamin to be processed further by the 
cells, and causes an accumulation of cobalamin in the 
lysosomes and possibly the endocytic vesicles. 
The combination of specific binding sites on the 
plasma membranes and the localization of TC II-vitamin B12 in 
the lysosomes after its internalization by the cell leads 
to the conclusion that the complex probably enters the cell 
by a process of binding site-mediated pinocytosis or 
adsorptive endocytosis (9) . 
Chloroquine does not affect the binding of TC II to the 
membrane binding sites and it is assumed that it does not 
influence the rate of endocytosis. Therefore the conclusion 
can be drawn that in the absence of chloroquine the real 
uptake of TC II-vitamin B12 is much higher than the observed 
uptake and that a part of the internalized vitamin B12 is 
released from the cells shortly after its uptake. 
This release of vitamin B12 was studied directly by 
incubation of isolated liver cells from rats which had been 
intravenously injected with [ 57co] vitamin B12 before the 
isolation procedure was started. When the injection was given 
shortly before the isolation of the cells the total amount 
of radioactivity could be released from the cells within 
2 hours of incubation. Apparently there was still TC II-
[57co] vitamin B12 attached to the binding sites, because 
a part of the radioactive label was instantaneously released 
from the cells. This early release increased with the 
concentration of added extracellular TC II but the 
subsequent release of cell-associated radioactivity was 
independent of the extracellular TC II concentration. The 
latter radioactivity was probably located in endocytotic 
vesicles, or the lysosomes. Measurement of the total release 
of vitamin B12 revealed that there is a more stable pool of 
vitamin B12 in the cell from which vitamin B12 is released 
steadily. The release of this endogenous vitamin B12 in 
absolute quantities exceeded the release of radioactive 
vitamin B12 but it amounted to only 15% of the total liver 
vitamin B12 content. Moreover, it was independent of extra-
cellular TC II concentrations. When [ 57co] CN-Cbl was 
administered 70 hours before the cell isolation, the release 
of 57co-radioactivity was proportional with the total vitamin 
B12 secretion, which means that in 70 hours the [
57
co] 
vitamin B12 was fully integrated into the stable pool. 
Our data on the release of vitamin B12 from isolated 
liver cells correspond with results from studies by Cooksley 
et al. (10,11), who observed releases of vitamin B12 by the 
perfused rat liver in vivo during 4 hours of 15%, 30% or 87% 
after the liver had been labeled with [ 57co] CN-Cbl 96 
hours, 18 hours and 0.16 hours before the perfusion was 
started. This release was not influenced by cycloheximide, 
sodium phenobarbitone or the injection of large amounts of 
unlabeled vitamin B12 18 hours before the perfusion. In our 
studies cycloheximide and puromycin were found to be 
ineffective on the release of vitamin B12 from the labile 
and the stable pool. This indicates that protein synthesis 
is not directly involved in the release of vitamin B12 from 
the cell. 
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Excretion of radioactive vitamin B12 in the bile was 
low, compared wi-th the secretion by the isolated liver cells 
in our study and also in comparison with the secretion by 
the perfused rat liver in the studies of Cooksley and Tavill 
(ll) 
In conclusion the experimental results are indicative 
for rapid exchange between vitamin B12 in the blood and a 
labile intracellular pool of the liver cell, presumably 
involving a process of adsorptive endocytosis. A small 
fraction of the internalized vitamin B12 is probably retained 
by the cell to meet its own metabolic requirements and to 
replenish the slowly releasing stable pool. 
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chapter 5 
PURIFICATION OF HUMAN TRANSCOBALAMIN II-CYANOCOBALAMIN BY AFFINITY 
CHROMATOGRAPHY USING A THERMOLABILE IMMOBILIZATION OF CYANOCOBALAMIN 
5.1. Summary. 
Transcobalamin II was isolated from Cohn fraction III 
of pooled human plasma with an affinity chromatography 
technique followed by conventional separation methods. The 
affinity material was prepared by a direct thermolabile 
attachment of hydroxocobalamin (OH-Cbl) to AH-Sepharose 4B. 
The specificity of the affinity ligand for Cbl-binding 
proteins was improved by a conversion into cyanocobalamin 
(CN-Cbl), with maintenance of the thermolabile linkage. 
The total purification procedure included successively 
CM-Sephadex batchwise elution, affinity chromatography, 
Sephacryl S 200 gel filtration and DEAE-Sepharose CL-6B ion-
exchange chromatography with a linear and a concave gradient 
elution. The final product was obtained with a yield of 55% 
6 
and a purification factor of 1.1 x 10 . The specific CN-Cbl 
binding capacity was 0.98 mol CN-Cbl/mol TC II. In dodecyl 
sulphate polyacrylamide gel electrophoresis one major protein 
band was observed at a molecular weight of 37 000 and a 
faint band at a molecular weight of 29 000. A considerable 
shift from the first to the second band occurred, when the 
protein was incubated with s-mercaptoethanol or dithiothrei-
tol before electrophoresis. 
At the same time three faint protein bands appeared at 
molecular weights of 24 000, 18 000 and 13 000. This suggests 
a dissociation of the TC II molecule in smaller subunits. 
In polyacrylamide gel isoelectric focusing the pure 
preparation appeared to be composed of several isoproteins 
with isoelectric points ranging from pH 6.2 to 6.8. The 
pure material was labeled with 125 I using immobilized 
ss 
lactoperoxidase. The labeled product was analyzed with 
gel filtration and ion exchange chromatography and appeared 
to be unaltered. 
5.2. Introduction. 
In the preceeding chapters the binding of TC II-[ 57 co] 
CN-Cbl to isolated rat liver plasma membranes and the uptake 
of TC II-[ 57co] CN-Cbl by isolated rat liver parenchymal 
cells have been described. Because the radioactive label was 
in the vitamin moiety of the complex the results of the 
experiments gave almost no data on the role and fate of the 
protein part. The study of the uptake and digestion of the 
transport protein necessitates the incorporation of a radio-
active label in the protein. For this the protein had to be 
purified to homogeneity first. A review of the existing 
methods of purification for TC II was given in section 1.2.5. 
In this chapter a new procedure is presented which is based 
on the method of Nex¢ (1,2), and which makes use of the 
property of hydroxocobalamin to form a thermolabile linkage 
with certain aminogroups. 
We found that the method of Nex¢ was inadequate for the 
purification of TC II from rat or human plasma, because also 
large amounts of non-TC II-plasma proteins were retained by 
the affinity column, which were very difficult to remove in 
later purification steps. 
A simple modification is described which effectively 
reduced the non-specific binding of proteins to OH-Cbl. It 
appeared to be possible to convert the immobilized OH-Cbl to 
CN-Cbl by elution of the column with a buffer containing 
cyanide. Under the influence of the cyanide OH-Cbl changes 
to di-CN-Cbl, which after omission of KCN from the buffer 
is converted to mono-CN-Cbl under maintenance of the thermo-
labile linkage. CN-Cbl has almost no affinity for plasma 
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proteins other than TC II and cobalophilin, in contrast to 
OH-Cbl which also avidly binds to albumin and other proteins 
(3,4,5,6). The effect of this modification, the result of a 
representative purification procedure and the characteriza-
tion of the isolated material are presented in the following 
sections. 
5.3. Methods. 
AH-Sepharose was used as the insoluble matrix. 1 g AH-
Sepharose 4B was swollen in 200 ml 0.5 M NaCl for 15 min and 
washed with another 300 ml 0.5 M NaCl. The swollen Sepharose 
was directly incubated with OH-Cbl in about 2 ml 0.1 N NaHC0 3 , 
0.5 M NaCl, pH 8.2. The amount of OH-Cbl, which was incubated 
with the Sepharose, was about 10 times in excess of the 
binding capacity of the sample from which the binding proteins 
were going to be isolated. This because the average efficiency 
of the coupling procedure is 20-30% and an excess of about 
100% of immobilized cobalamin in comparison to the binding 
capacity of the sample is thought to be desirable. 
For the detection of TC II in further purification steps 
AH-Sepharose was incubated with a mixture of labeled and 
unlabeled OH-Cbl. ( 57 Co] OH-Cbl was prepared from [ 57 Co] 
CN-Cbl by exposure to a 60 W tungsten lamp at a distance of 
15 em for 18 hours in 8 rnM HCl, according to Mahoney et al. 
(7). The cuvette was thermostatically kept at 4°C. The 
Sepharose suspension was incubated with OH-Cbl for about 
18 hours at room temperature in a rotary mixer, cooled on 
ice for 30 min and poured into a precooled glass column 
(1.5 >. 5.5 em). The Sepharose was washed with 50 ml of 20 mM 
sodium phosphate, 1M NaCl, 10 mM KCN, buffer pH 8.2 to 
convert the OH-Cbl to di-CN-Cbl. The excess of Cbl in the 
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effluent was measured spectrophotometrically to establish 
the coupling efficiency. KCN was removed with 200 rnl of the 
phosphate-NaCl buffer without KCN and at the same time the 
di-CN-Cbl was converted to mono-CN-Cbl. In this form the 
column was used for the purification procedure. 
5.3.2. Purification of human transcobalamin II. 
-------- -----
A representative purification procedure is described in 
detail. 80 1 of 10 rnM sodium phosphate, 0.1 M NaCl, buffer 
pH 5.2 was added to 19 kg of Cohn fraction III, and the 
suspension was stirred continuously for 12 hours at 4°C. 
Insoluble material was allowed to settle and the supernatant 
was filtered over nylon gauze (63~}. The filtrate was stirred 
for another 12 hours with 100 g of dry CM-Sephadex C-50. The 
Sephadex was collected by filtration over nylon gauze and 
washed first on the gauze and afterwards on a glass filter 
with 10 1 of 10 rnM sodium phosphate, 0.05 M NaCl, buffer 
pH 5.2. TC II was eluted from the Sephadex by stirring the 
suspension in 1.5 1 of 0.2 M Tris, 1M NaCl, pH 8.2. The 
Sephadex was washed with another 400 ml Tris buffer. The 
total filtrate, about 3300 ml, was centrifuged for 2 hours 
at 105 000 x g. The supernatant was passed through filter 
paper (S&S 589 3) to remove floating lipid material. The 
cobalamin-binding capacity was measured and the total volume 
was applied to the affinity column, which contained 210 ~g 
of immobilized CN-Cbl with a specific activity of 19 175 
cpm/~g, at a flow rate of 100 ml/hour. The column was washed 
with 400 ml cold 20 roM sodium phosphate, 1M NaCl, 0.02% 
NaN 3 , pH 7.4 and during this washing the Sepharose was 
resuspended and allowed to settle in order to remove 
particulate material. Elution of the TC II-CN-Cbl took 
place after incubation of the column for 10 hours at 37°C 
and washing with about 5 ml of warm phosphate-NaCl buffer. 
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After another 10 hours at 37°C the remainder of the TC II-
CN-Cbl and free cobalamin were eluted with 4 ml of warm 
buffer and the two eluates were combined. 
The TC II-CN-Cbl solution was subsequently applied to 
a Sephacryl S 200 column (2.6 x 90 em) and elution took 
place with the same phosphate buffer. The fractions 
containing TC II-CN-Cbl, detectable by their 57co-radio-
activity, were pooled and concentrated by ultrafiltration 
on a YM 10 membrane (Amicon) . After this concentration the 
buffer was changed to 50 rnM Tris/HCl pH 8.25 as a 
preparation for the next purification step, DEAE-Sepharose 
ion exchange chromatography. The concentrate was put on a 
0.9 x 4 em column of DEAE-Sepharose CL-6B and eluted with 
a linear gradient from 0 to 225 rnM NaCl in 50 mM Tris/HCl 
pH 8.25 with a total volume of 200 ml. 
The concentrated fractions containing TC II-CN-Cbl were 
again brought in 50 rnM Tris/HCl pH 8.25 and applied to a 
second DEAE-Sepharose column. For the elution a concave 
gradient from 0-150 mM NaCl was created by a two-pump system 
in which the efflux from the mixing chamber was 14 times the 
influx of the high salt solution into the mixing chamber (8) 
The total volume of the gradien.t was 200 ml. The fractions 
containing TC II-CN-Cbl were pooled and concentrated on a 
YM-10 ultrafiltration membrane. 
The different purification products were subjected to 
measurements of the CN-Cbl-binding capacity or the vitamin 
B12 content and of the total protein in order· to establish 
the specific vitamin B12-binding capacity of the.isblated 
material. The methods for the measurements of binding 
capacity and vitamin B12 concentration are described in 
section 2.2.2 and 2.2.3 respectively. 
Protein was measured according to Lowry et al. (9), 
using bovine serum albumin or human serum albumin protein 
standard (Kabi, Stockholm) as a reference. Both standards 
gave identical results. 
Dodecyl sulphate polyacrylamide gel electrophoresis 
was carried out according to Fairbanks et al. (10). Electro-
phoresis was performed at 2.5 rnA/gel until the tracking dye, 
pyronine Y, reached the bottom of the electrophoresis tube. 
The gels were fixed and stained with Coomassie brilliant 
blue. 
Thin layer polyacrylamide gel isoelectric focusing was 
performed with a modification of the method of Vesterberg 
{11). The gel was composed of 13.5 ml 30.5% acrylamide, 
15 ml 1% NN'-methylene bisacrylamide, 27 ml H2o, 0.65 g 
Triton X-100, 7.5 g sucrose, 1.0 ml Ampholine pH 5-7, 1.0 
ml Ampholine pH 6-8, 1 ml Ampholine 7-9, 1 ml 0.0055% ribo-
flavin and polymerization was induced by a daylight tube 
lamp. The samples were applied in small{Sxl0x1rnm) basins in 
the gel. The cathode solution was 0.1 M NaOH, the anode 
solution 0.1 M H3Po 4 . 
Focusing was done in a LKB Multiphor apparatus for 
90 min at 4°C. At the end of the focusing time the pH 
gradient was measured with an Ingold Surface electrode type 
104033.104. The proteins were fixed in 50% methanol/7.5% 
TCA and stained with Coomassie brilliant blue. 
40 mg lactoperoxidase (Boehringer, Mannheim, Germany) 
was dialyzed for 24 hours against 1 1 of 0.1 M NaHC0 3 buffer 
pH 8.0, containing 0.5 M NaCl. The dialyzed protein was 
coupled to AH-Sepharose 4B according to the instructions of 
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the manufacturer. Unbound protein was removed by filtration 
and the gel was finally washed with distilled water and 
lyophilized. The total amount of lyophilized material was 
520 mg. 
The enzymatic activity was determined by means 
2.2•-azino-di[ 3-ethyl-benzthiazoline sulfonate {6) 
of a 
{ABTSR)-coupled reaction. The increase of extinction at 
436 nm was used 
2 29.3 em /vmol) . 
1cm 
as a measure of enzyme activity (E 436 
5 mg of lyophilized lactoperoxidase - Sepharose 
(LP-Sepharose) were swollen in 0.07 M potassium phosphate 
buffer, pH 5.5 and added to the reaction mixture, which 
contained 20 rnM ABTS and about 0.25 rnM H2o2 in the same 
buffer. During the reaction the Sepharose was kept in 
suspension. The enzyme activity was found to be 900 mU/mg 
lyophilized LP-Sepharose and the percentage of coupled and 
recovered enzyme activity was 10%. 
The protein labeling was carried out according to David' 
{12). 0.5 mg LP-Sepharose was swollen in 0.5 ml 20 rnM sodium 
phosphate, 0.15 M NaCl, pH 7.4 in a 1.5 ml micro reaction 
vessel. The suspension was centrifuged for 1 min at 8 000 
x g and the supernatant was re~oved. 0.9 ml phosphate-NaCl 
buffer was added to the pellet, followed by 0.1 ml (30 ~g) 
TC II-CN-Cbl, 0.1 ml ( 1 mCi) [ 1251] Nai and 0.1 ml 0.122 ml'l 
KI. At 0, 10 and 20 min 10 ~1 0.03% H2o2 was introduced and 
the reaction vessel was rotated for 30 min. After the 
incubation the mixture was centrifuged for 2 1 at 8 000 x g 
to remove the LP-Sepharose beads and the supernatant was 
collected. The Sepharose pellet was washed twice with 
incubation buffer and the collected supernatants were 
applied to a Sephadex G75 column {1.6 x 70 em). The sample 
was eluted with 20 mM sodium phosphate, 1 H NaCl pH 7.4. The 
2 ml fractions were collected in siliconized tubes which 
contained 100 ~1 of 1.8% human serum albumin in saline. The 
latter precautions were taken in order to reduce absorption 
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of the labeled protein, which amounted to 62% in normal glass 
tubes, 30% in siliconized glass tubes and 9% when also 
albumin was added. 
The TC II-containing fractions were pooled and concen-
trated by ultrafiltration. The vitamin BS 2 content was 
measured by radioassay and a specific 12 I-radioactivity of 
190 cprn/pg CN-Cbl was calculated. 
5.4. Results. 
Our improvement of the affinity chromatography technique 
was based on the results of purifications of transcobalamin 
II from rat plasma using the unmodified method of Nex¢ (4). 
When rat plasma with a total CN-Cbl-binding capacity of 
0.16 nmole was applied to a OH-Cbl-Sepharose column, 59 
nmoles of protein-bound OH-Cbl were recovered in the 37°C 
eluate. This means that other plasma proteins also showed 
a high affinity for the OH-Cbl in the column. Because it is 
known that for instance serum albumin readily binds OH-Cbl 
but not CN-Cbl (13) it was tried to prepare a CN-Cbl-
Sepharose column. CN-Cbl-Sepharose was obtained from OH-Cbl-
Sepharose by successive rinses with a CN containing and a 
CN -free buffer so that OH-Cbl was converted first to di-CN-
Cbl and then to mono-CN-Cbl, as was illustrated by the 
absorption spectra of the 37°C eluates in each of the three 
stages of preparation (figure 5.1). When the rat serum was 
applied to such a CN-Cbl-Sepharose column all protein-bound 
CN-Cbl in the eluate was bound to TC II, which means that 
the non-specific binding was completely eliminated. 
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fig. 5.1. Spectra of affinity column eluates.-
cobalamin from an unconverted column; 
hydroxo-
------J 
dicyanocobalamin from a converted column with CN 
in the elution buffer; ~ cyanocobalamin from 
a converted column which was previously rinsed 
with CN free buffer. All samples were diluted in 
the respective elution buffers and the same buffer 
was used as a reference. The spectra were recorded 
on a Perkin Elmer 124 spectrophotometer. 
5.4.2. Purification of human transcobalamin II. 
With this improved affinity chromatography technique the 
purification of TC II was started with Cohn fraction III from 
human plasma. The total vitamin B12-binding capacity of the 
Cohn fraction solution was 170 wg. The insoluble material 
contained also some binding capacity, but a second extraction 
was not worthwhile, because the yield and the specific binding 
activity were low. The vitamin B12-binding capacity of the 
first supernatant was used as the 100% value for the 
calcula·tion of the yield of the purification. 
Using batchwise CM-Sephadex elution the TC II was 
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fig. 5.2. Elution profile of the affinity column eluate on a 
Sephacryl S 200 column (2.6 x 90 em) equilibrated 
with 20 mM sodium phosphate, 1 M NaCZ buffer_, pH 
? 2 A 57 d" t" . . . _, 280 ; -------, Co-ra -z..oac -z..v-z..ty. 
Fraction volume was 2.8 ml and the elution 
velocity was 10 ml/hour. 
recovered from the supernatant in a volume of 3.3 l, with a 
17-fold purification and only a 10% loss of binding capacity. 
The specific vitamin B12-binding capacity of the eluate 
from the affinity column could not be calculated directly, 
because the eluate contains a mixture of free and bound Cbl. 
The amount of bound cyanocobalamin was determined in the 
following purification step: the Sephacryl S 200 column. The 
total amount of bound cyanocobalamin was divided by the total 
amount of protein in the eluate of the affinity column to 
calculate the specific binding capacity. The elution profile 
of the Sephacryl S 200 column is given in figure 5.2. The 
specific binding capacity was 16.3 ~g vitamin s 12 ;mg protein, 
which suggests a purity of about 50%. Further purification 
was carried out with DEAE-Sepharose CL-6B ion exchange 
chromatography and the elution profile with a linear salt 
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fig. 5.3. Elution pattern of the first DEAE-sepharose CL-6B 
column. The column (0.9 x 4 em) was equilibrated 
with 50 mM TrisjHCl pH 8.25 and elution took place 
with a linear salt gradient from 0 to 225 mM NaCl 
with a volume of 200 ml. ---- .. A280 ; --------5? d. . . Co-ra ~oact~v~ty; conductivity. Fraction 
volume was 2 ml and the elution velocity was 
15.8 ml/hour. 
gradient is presented in figure 5.3. The shoulder of non-TC 
II protein before the TC II peak was eliminated by DEAE-
Sepharose chromatography with a concave salt gradient 
(figure 5.4). Measurement of protein and vitamin B12 in the 
final product gave a specific binding activity of 34.8 ~g/mg 
or 0.98 mole CN-Cbl per mole TC II (molecular weight TC II 
38 000), which means that the preparation was almost pure. 
The purification factor was 1.1 x 10 6 with a yield of 55%. 
A summary of the results of the purification procedure. is 
given in table 5.1. 
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Table 5.1. Purification of human transcobaZamin II-cyanocobalamin 
step of volume total protein total CN-Cbl- specific CN-Cbl- purification 
purification (ml) (mg) binding capac. binding capacity factor 
("g) ( "g/mg) (mol/mol) 
Cohn fraction 95000 5.36x10 6 170 3.17x10 -5 8.9x10 -7 1 
III 
(solubilized) 
CM-Sephadex 3300 0.27x10 6 153 -7 -4 5.66x10 0.16x10 18 
batchwise 
elution 
affinity 11.4 31 120 3.87 0.108 l. 22x10 5 
chromatography 
on CN-Cbl-
Sepharose 
Sephacryl S200 7. 1 5.84 95.2 16.3 0.46 5.14x10 5 
gel filtration 
DEAE-Sepharose 6.9 3.93 91.0 23.2 0.65 7.32x10 5 
CL-6B 
linear gradient 
DEAE-Sepharose 9.0 2. 6 7 93.0 34.8 0.98 1.10x10 6 
CL-6B 
concave gradient 
yield 
( %) 
100 
90 
71 
56 
54 
55 
radioactivity 
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fig. 5.4. Elution pattern of the second DEAE-sepharose CL-6B 
column. The column (0.9 x 4 em) was equilibrated 
with 50 mM Tris/HCl pH 8.25 and elution took place 
with a concave gradient from 0 to 150 mM NaCl with 
a total volume of 200 ml. .. A280 ; -------- .. 57 d" . . d . . . Co-ra &oact-z-v-z-ty;-··-··-_,con uct-z-v-z-ty. Fract-z-on 
volume was 2.0 ml and the elution velocity 15.2 
ml/hour. 
The pure transcobalamin II-CN-Cbl was subjected to 
dodecyl sulphate polyacrylamide gel electrophoresis under 
reducing and non-reducing conditions (figure 5.5). In electro-
phoresis without a reducing agent a single major band was 
observed at a molecular weight of 37 000 and a faint band, 
less than 5% in densitometric analysis, with a molecular 
weight of about 29 000, even if as much as 75 ~g TC II was 
applied. The incubation with 1% S-mercaptoethanol, 10 mM or 
50 mM dithiothreitol resulted in a 50% decrease of 37 000 
molecular weight material, an increase of the 29 000 band, 
and the appearance of some faint bands at 24 000, 18 000 
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fig. 5.5. Dodecyl sulphate polyacrylamide gel electrophoresis 
of 12.5 ~g of transcobalamin II (A and B) and of a 
mixture of albumin~ aldolase and myoglobin (C~ 10 
~g each). Preparation and electrophoresis of the 
samples in A and C were carried out in the presence 
of 50 mM dithiotreitol. The characters a~b~c~d~ and 
e refer to fig. 5.6 in which the relative mobilities 
are used for the calculation of the molecular weights. 
and 13 000. The molecular weights were estimated by comparison 
with three marker proteins (figure 5.6). From these data it 
is concluded that about 50% of the TC II dissociates into 
smaller subunits under reducing conditions. Electrophoresis 
patterns were not different whether preincubation was carried 
out for 2 hours at 37°C or for 3 min at 100°C. 
Polyacrylamide gel isoelectric focusing of the pure 
TC II-CN-C~l was initially not successful, because the 
protein precipitated during the procedure even before it had 
reached the area of its isoelectric point. This was probably 
a result of the poor solubility of TC II at low ionic strength. 
The addition of 1% Triton X-100 improved the solubility. 
Figure 5.7 shows an IEF-pattern of the pure TC II preparation 
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fig. 5.6. Plot of the molecular weights of the tkree marker 
proteins versus their relative mobilities on 
dodecyl sulphate polyacrylamide gel electrophoresis 
(figure 5.5). The characters a~b~c~d and e 
represent the different polypeptide chains in the 
TC II preparations: a~ 37 000; b~ 29 000; 
c~ 24 000; d~ 18 000; e~ 13 000 molecular weight. 
in a pH gradient from 4.9 to 7.4. The protein is concentra-
ted in an area from pH 6.2 to pH 6.8, in which at least two 
double bands around pH 6.30 and 6.45 are visible. 
5.4.4. ~2~I=l~b~l~ng ~f_t~e_i~o!a!e~ !r~n~c~b~l~m!n_II-_ 
£Y~n£C2b~l~m~n~ 
Portions of 30 ~g pure TC II were labeled with 125 I 
with the use of immobilized lactoperoxidase. After the 
incubation the labeled protein and the other constituents 
were separated by gel filtration on Sephadex G-75. A 
representative elution pattern is shown in figure 5.8. 
The symmetrical radioactivity peak completely coincided 
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fig. 5.7. Polyacrylamide gel isoelectric focusing of 45 ~g 
of pure TC II. The diagram indicates the course of 
the pH over the gradient from anode to cathode. 
with the light absorption peak at 280 nm around fraction 
32 and the elution volume was the same as for TC rr-[ 57co] 
CN-Cbl. This indicates that the molecular weight did not 
change by the labeling procedure. 
A further control of the integrity of the labeled 
protein was performed by means of ion exchange chromatography. 
A small amount of [ 125r] TC II-CN-Cbl and about the same 
amount of partially purified TC rr-[ 57co] CN-Cbl were mixed 
and separated on a DEAE-Sepharose column with a linear salt 
gradient. The elution pattern is shown in figure 5.9. Both 
peaks of radioactivity were eluted at exactly the same salt 
concentration, which indicates that the labeling procedure 
did not cause a significant change of the isoelectric point. 
The most important characteristic of the labeled protein, 
its function in the cellular up-take of vitamin B12 , is 
analysed in the following chapter. 
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fig. 5. 8. Separation of 125 I-labeled TC II-C/1-Cbl and free 
(1 25r}llai by gel filtration on a Sephadex G ?5 
column (1. 6x65 em). Elution buffer was 20 mM sodium 
phosphate~ 1 M NaCl~ pH ? . 4. 0---0 125 I-radioacti-
vity; A 280 . Fraction volume was 1.8 ml and 
the elution velocity was 25 ml/h. 
5.5. Discussion. 
Purification of transcobalamin II with conventional 
methods is unsatisfactory, because it is almost impossible 
to obtain a fair yield of the pure product. The affinity 
chromatography technique described by Allen and Majerus (13), 
gave better recovery and has made the characterization of 
the purified material possible. This method has the 
disadvantage that it requires strong protein denaturation 
for a rather long time, which may inactivate the trans-
cobalamin. Weiss et al. (14) e.g. have reported that human 
intrinsic factor, which was purified by the method of 
Allen et al. (13) had a decreased affinity for the intestinal 
receptor, and denaturation of cobalophilin with this method 
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Fig. 5.9. Elution profile of a mixture of equal amounts of 
partially purified TC II-{ 57 Co} CN-Cbl and (1 25 I} 
TC II-CN-Cbl on DEAE-Sepharose CL-6B (bed volume 
2.5 ml). Elution was carried out with a linear 
gradient from 50 mM Tris~ pH 8.25 to 50 mM Tris~ 
225 mM NaCl~ pH 8.25. Fraction volume was 2 ml 
and the elution velocity was 16 ml/h. •---• 
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was suggested by Stenman (15). 
Nex¢ (1) has described an easier and more gentle 
affinity chromatography method for the purification of 
intrinsic factor and cobalophilins, in which OR-cobalamin 
is attached to immobilized 3.3'-diaminodipropylamine by a 
thermolabile linkage. When unsaturated serum is applied to 
such a column, only the vitamin B12-binding proteins are 
retained and eluted as saturated binding proteins from the 
column at 37°C. Initially we tried this method for the 
isolation of transcobalamin II from rat plasma. However, in 
the eluate of the affinity column only a very small fraction 
of the protein-bound OH-Cbl was coupled to TC II. Therefore, 
we investigated the possibility to incorporate CN-Cbl, which 
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shows less non-specific binding, in the affinity column. 
Direct incorporation proved to be impossible because 
CN-Cbl has no affinity for the 3.3'-diaminodipropylamine 
molecule. However, we observed that the OH-Cbl, when attached 
to the insoluble matrix, could be converted to CN-Cbl, by 
rinsing with a buffer containing cyanide, without losing the 
thermolabile linkage. Non-specific binding was completely 
absent because no other vitamin B12-binding proteins than 
TC II were detectable in the 37°C eluate. 
A further simplification of the method of Nex¢ was the 
coupling of OH-Cbl directly to AH-Sepharose instead of to 
the 3.3'-diaminodipropylamine-substituted CN-Br-Sepharose. 
Human transcobalamin II was purified from Cohn fraction 
III to homogeneity by CM-Sephadex ion exchange chromatography, 
affinity chromatography, gel filtration and DEAE ion exchange 
chromatography, successively. The use of isoelectric 
precipitation for the final purification, reported by Savage 
et al. (16), appeared to be irreproducible. Excellent separa-
tion of TC II from contaminating proteins was obtained with 
the Sephacryl S-200 column. Another important improvement in 
the yield of the overall procedure was the use of Amicon 
YM-10 ultrafiltration membrane for which TC II has only very 
low affinity in contrast to UM or PM-type membranes. 
The final product was virtually pure on the basis of the 
specific binding activity, calculated to be 0.98 mol CN-Cbl/ 
mol TC II. A slightly lower specific binding activity, 0.87 
mol CN-Cbl/mol TC II was obtained when the amount of CN-Cbl 
in the final preparation was calculated on the basis of the 
specific radioactivity of the OH-Cbl solution, which was 
used for the preparation of the affinity column. A possible 
explanation for this small difference is, that the [ 57co] 
OH-Cbl, as a result of the conversion with light in an acid 
environment, contained derivatives, which adhered to the 
AH-Sepharose but had lost their binding affinity for the 
TC II molecule. 
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The purity of the material was further established 
by means of dodecyl sulphate polyacrylamide gel electro-
phoresis. The small protein band at a molecular weight of 
29 000 does not seem to be a contamination but rather a sub-
fraction of TC II, because this band intensified considerably 
when preincubation and electrophoresis were carried out in 
the presence of reducing agents. In addition components with 
molecular weights of 24 000, 18 000 and 13 000 appeared. This 
suggests that our preparation contained a mixture of TC II 
as a single polypeptide chain with a molecular weight of 
37 000, and of TC II composed of two separate polypeptide 
chains with molecular weights of either 29 000 and 13 000 
or 24 000 and 18 000. Similar observations were described 
by Allen et al. (13 1 17), who concluded that native TC II is 
a single polypeptide chain and that the snaller polypeptide 
chains had been formed by an internal cleavage. We have tried 
to determine, whether proteolysis during the purification had 
caused the formation of the smaller fragments. However, the 
electrophoresis of a TC II-preparation, which was purified 
in the presence of diisopropylfluorophosphate in order to 
prevent proteolysis, gave exactly the same results. Therefore, 
whenever the formation of the smaller polypeptide chains 
was due to proteolysis this must have taken place before the 
purification. 
Polyacrylamide gel isoelectric focusing of pure TC II is 
extremely difficult because of the strong tendency of TC II 
to precipitate at low ionic strength. Recently Marcoulis et 
al. reported that they were unable to establish a typical 
electrofocusing pattern in a sucrose gradient (18). In our 
experience the solubility in the gel could be improved best 
by the addition of Triton X-100. TC II concentrated in a 
rather broad area between pH 6.2 and 6.8 in at least four 
discernable protein bands. These protein bands may represent 
TC II molecules in the different polypeptide chain 
configurations, which were demonstrated in the dodecyl 
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sulphate polyacrylamide gel electrophoresis, but another 
explanation is the occurrence of isoprotein forms. Genetic 
polymorphism of transcobalamin II has been reported by 
Frater-SchrOder et al. (19) and by Daiger (20). Because 
there is evidence that TC II is synthesized by different 
tissues {21,22) it is tempting to speculate that these 
tissues produce slightly different TC II molecules. 
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chapter 6 
BINDING, UPTAKE AND DEGRADATION OF (!25!] TRANSCOBALAMIN II-CYANOCOBALAMIN 
BY ISOLATED RAT LIVER CELLS AND THE PERFUSED RAT LIVER 
6.1. Sununary. 
Isolated rat liver parenchymal cells were incubated 
with human TC II-CN-Cbl, which had been purified to 
homogeneity by means of affinity chromatography and 
enzymatically labeled with radio-iodine. The binding and 
uptake followed the same biphasic pattern as the binding and 
uptake of TC rr-[ 57co] CN-Cbl, i.e. a steep rise of cell 
bound radioactivity in the first few minutes, and a continuous 
temperature dependent increase in the following two hours. 
These steps are interpreted as a rapid binding of the complex 
to the outer cell membrane and a gradual entrance of the 
complex into the cell. With a lag of about 15 min acid-
soluble radioactive material appeared in the medium as a 
result of intracellular proteolysis of TC II and increased 
linearly during the next two hours of incubation to about 
1.5 times the amount of radioactive TC II inside the cell. 
The rate of uptake, i.e. the increase with time of intra-
cellular radioactivity plus degradation of TC II, as a 
function of the extracellular concentration of TC II-CN-Cbl 
showed a partial saturability. Addition of 10 nM unlabeled 
pure TC II-CN-Cbl led to a suppression of the saturable 
component of the uptake. After correction of the total 
uptake for these non-specific components, a curve of specific 
saturable uptake was obtained. The uptake of human [ 125 I] 
TC II-CN-Cbl was suppressed by purified rat TC II-CN-Cbl 
indicating that human and rat TC II compete for the same 
binding sites on the cell 
[125 J human I TC II-CN-Cbl 
surface. 
were not 
Binding and 
affected by 
uptake of 
EDTA or EGTA, 
The lysosomotropic agent chloroquine reduced the degradation 
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of TC II and consequently caused an accumulation of radio-
active TC II within the cell. In additional studies using 
liver perfusion the uptake and degradation of TC II were 
quantitatively and qualitatively similar to the uptake and 
degradation by liver cells incubated in suspension. 
6.2. Introduction. 
The results described in chapter 4 suggested that TC II-
vitamin B12 is taken up by the liver cell by a pinocytotic 
mechanism and subsequent inclusion in the lysosomal .system. 
Especially the experiments with the lysosomotropic agent 
chloroquine made it likely that proteolysis of TC II is a 
prerequisite for the normal intracellular transport of 
vitamin B12 . In this chapter experiments are described which 
were designed to find additional evidence for this proteolytic 
process. For this purpose isolated liver cells and the 
125 perfused rat liver were incubated with I-labeled TC II and 
the binding, uptake and degradation of TC II degradation 
products have been measured. 
6.3. Methods. 
Liver parenchymal cells were isolated as described in 
section 2.4. The cells were washed and finally suspended in 
DMEM in a concentration of 3.6 x 10 6;m1. All glassware was 
siliconized. 
108 
6.3.2. ~r~p~r~tlog Qf_h~m~n_(~2~IJ ~C_I!-~N=C~l_agd_r~t 
TC II-CN-Cbl. 
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Purification and 125 I-labeling of human TC II-CN-Cbl 
have been described in chapter 5. It was established that 
the 125I-labeled product did not differ from partially 
purified TC Ir-( 57co] CN-Cbl in gel filtration and ion 
exchange chromatography. 
Rat TC II was partially purified by means of affinity 
chromatography. 300 ml rat serum was centrifuged for l hr at 
lOS 000 x g and applied to a CN-Cbl-Sepharose column, which 
was prepared by incubation of l g AH-Sepharose 4B with 5 ~g 
OH-Cbl and converted to CN-Cbl-Sepharose as described in 
section 5.3.1. TC II was eluted at 37°C in 15 ml 20 mM sodium 
phosphate, l M NaCl, pH 7.4 and bovine serum albumin was 
added to a concentration of 4 rng/rnl. The total solution was 
dialysed for 72 hours against 3 x 1 1 DMEM at 4°C, 
centrifuged for l hour at 105 000 x g and the CN-Cbl 
concentration in the supernatant was determined by radio-
assay. The purification factor was estimated to be about 
6 x 10 4 , analogous to the affinity chromatography step in 
the purification of human TC II. The yield of TC II-CN-Cbl 
in the final product was 96%. 
The standard incubation was identical with the procedure 
described in section 4.3.3 with the exception that in the 
present experiments [125I] TC II-CN-Cbl was used. 
Degradation of TC II was judged by the appearance of 
acid soluble material in the medium and the cells. During 
the incubation of ( 125 I ]Tc II-CN-Cbl with the cells, 
duplicate 0.5 ml samples were taken and centrifuged through 
silicon oil as described (section 2.5). 0.2 ml aliquots of 
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the supernatant were mixed with 0.3 ml 3.3% bovine serum 
albumin and 0.5 ml 20% perchloric acid. After incubation for 
30 min at 4°C the precipitate was removed by centrifugation 
for 2 min at 8 000 x g and 0.8 ml supernatant was removed 
and counted. Blank values were obtained by incubations of 
[125I] TC II-CN-Cbl without cells under the same conditions. 
Degradation of TC II was defined as the difference between 
the amount of acid soluble radioactivity at any time of 
incubation and the corresponding blank value. The intra-
cellular degradation products were determined by measuring 
the radioactivity in 0.05 ml aliquots of the perchloric 
acid layer of the silicon oil centrifugation tubes. In 
general these values were low and negligible. 
Perfusion of rat livers was performed in situ at 37°C 
under initial ether anesthesia. The cannulation of the portal 
vene and the inferior vena cava was carried out as described 
in 2.4. Before insertion of the perfusion cannulas the main 
bile duct was cannulated with a Braunule OG20. The liver was 
first perfused with about 200 ml DMEM with 0.09% human serum 
albumin to wash out the blood and then the perfusate was 
changed to DMEM with 0.09% human serum albumin and 450 pM 
[12SI l TC II-CN-Cbl. The recirculating extracorporeal 
perfusion volume was 100 ml, from which 2 ml samples were 
taken at 5, 15, 30' 6 0' 90 and 120 min for determination of 
the total amount of radioactivity and the amount of acid 
soluble 125 I-radioactivity. Biliary excretion of radioactivity 
was determined in bile samples, collected over 30 min periods. 
At the end of the perfusion the liver was rinsed with fresh 
TC II-CN-Cbl free perfusate, excised and the total radio-
activity in the liver was measured. 
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fig. 6.1. Binding and uptake of {1 25 I }Tc II-CN-Cbl by 
isolated liver parenchymal cells at three different 
temperatures. The concentration of [ 125I} TC II-
CN-Cbl was 320 pM. The points are the mean of 
duplicate measurements. 
6.4. Results. 
The studies on binding and uptake of [ 125 r ]Tc II-CN-Cbl 
by isolated rat liver parenchymal cells showed a rapid binding 
to the surface of the cells in the first few minutes of the 
incubation, and a gradual temperature dependent uptake in the 
following two hours (figure 6.1). The distinction between 
binding and uptake was made on the basis of the biphasic 
nature of the time dependent uptake as described in 
section 4.4.1. At o0c the initial increase in the cell-
associated radioactivity was less rapid and the binding 
seemed to go to completion in the next 60 min. 
The production of acid soluble material at the three 
different temperatures, illustrated in figure 6.2, started 
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fig. 6.2. Degradation of (1 25r }Tc II-CI!-Cbl by isolated 
liver parenchymal cells at three different 
temperatures. The concentration of { 125I} TC II-
CN-Cbl was 320 pM. The points are the mean of 
duplicate measurements. 
between 5 and 15 min of incubation and continued in a linear 
fashion for the next two hours, at least at 30°C and 37°c. 
At 0°C no production of acid soluble material was observed. 
From this experiment it can be calculated that at 37°C about 
75% of the TC II taken up by the cells is degraded during 
the two hours of incubation and secreted as acid soluble 
material. 
[ 125 r ]Tc II-CN-Cbl incubated in medium without cells 
remained completely intact as is demonstrated in figure 6.3. 
By incubation with a cell homogenate, which was obtained by 
sonication of an amount of cells equal to the standard 
incubation, no acid soluble material was formed at the normal 
pH 7.4, whereas at pH 5.6 TC II was degraded rapidly. With 
the cell homogenate free lysosomal proteolytic enzymes are 
introduced in the incubation mixture, but these enzymes have 
an acid pH optimum and are inactive at pH 7.4. Therefore the 
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fig. 6.3. Degradation of { 125I} TC II under various 
circumstances measured by the appearance of acid 
soluble material in duplicate samples of the medium. 
The { 125r} TC II-CN-Cbl concentration was ?30 pM. 
absence of acid soluble material in the incubations without 
cells or with disrupted cells at pH 7.4 indicates that in 
the normal incubations no other factors than the intact 
viable cells are responsible for the observed degradation. 
The uptake and degradation of [125 r ] TC II-CN-Cbl by the 
perfused liver are summarized in figure 6.4. Perfusions were 
carried out with 10 mM NH 4Cl, with 2.5 rnM iodoacetamide or 
without special additives. NH 4Cl has an inhibiting effect 
on lysosomal proteolysis by way of an increase in the intra-
lysosomal pH (1), whereas iodoacetamide causes a non-selec-
tive, irreversible inactivation of enzymes with essential 
SH-groups (2). The production of acid soluble material was 
measured with 30 min intervals and the liver radioactivity 
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in perfusate 
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fig. 6.4. Degradation and uptake of (1 25I} TC II-CN-Cbl by 
perfused rat livers. On the left side the increase 
in acid soluble material in the perfusate is plot-
ted versus the time of perfusion: •---• _, control; 
"---A_, with 10 mM NH4Cl;a---ll_, with 2.5 mM 
jodoacetamide. On the right the distribution of 
radioactivity in the liver and the acid soluble 
radioactivity in the perfusate at 120 min is 
illustrated. C: control cells_, N: NH 4Cl and I: 
iodoacetamide. 
was measured after 120 min of perfusion. 
In the control experiment the degradation was about 
twice the amount of radioactivity in the liver at 120 min. 
NH 4Cl caused a decrease in the production of acid soluble 
material and an accumulation of intracellular radioactivity, 
but the total amount of processed TC II was 20% less. 
In the presence of iodoacetamide no degradation occurred 
within 90 min, after which the perfusion had to be dis-
continued, because of extensive leakage of the liver tissue. 
There was little difference in the amount of liVer radio-
activity in comparison with the control experiment. 
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Assuming that the total liver contains about 9 x 10 8 
parenchymal cells the uptake in the perfusion experiment was 
9 about 1.8 pmoles/10 cells, whereas the degradation was about 
3.6 pmoles/10 9 cells. In comparison with similar data obtained 
with isolated liver cells (6.4 pmoles/10 9 cells for binding, 
uptake and degradation at 400 pM [125r] TC II-CN-Cbl) the 
values are of the same order of magnitude. 
The excretion of 125 r-activity in the bile was low, 
0.1 pmole in the control experiment, 0.05 pmole in the 
presence of NH 4Cl and 0.005 pmole with iodoacetamide. With 
iodoacetamide the bile production stopped after 60 min. 
6.4.3. ~i~d~n2,_uEt~k~ ~n~ ~e~r~d~t~o~ ~n_r~l~t~o~ !o_t~e­
concentration of TC IT-vitamin B12 . 
The competitive effect of unlabeled partially purified 
rat TC II-CN-Cbl on [ 125 r] TC II-CN-Cbl at a concentration 
of 420 pM was studied (figure 6.5) and it was demonstrated 
that with 5 nM unlabeled rat TC II-CN-Cbl [ 125 I] TC II-CN-
Cbl binding was depressed to zero, the uptake to 45% and the 
degradation to 67% of the original level. This suggests 
either a relatively high level of non-specific uptake of 
[ 125 I ] TC II at this [ 125 r ] TC II-CN-Cbl concentration or 
a partial competition between human [ 125 I] TC II-CN-Cbl and 
rat TC II-CN-Cbl. 
To discriminate between these two possibilities a second 
experiment was carried out in which the competition between 
human [ 125 I] TC II-CN-Cbl and unlabeled human TC II-CN-Cbl 
was investigated. The unlabeled TC II was purified by affinity 
chromatography on CN-Cbl-Sepharose, as described in chapter 
5, starting with the CM-Sephadex eluate from Cohn fraction 
h . . l . f [125 J III. In t lS experlment severa concentratlons o I 
TC II-CN-Cbl in the range from 100-700 pM were added to 
the liver cells with and without 10 nM unlabeled TC II-CN-
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fig. 6.5. The competitive effect of unlabeled rat TC II-CN-
Cbl on the binding~ uptake and degradation of 
human { 125I} TC II-CN-Cbl. The concentration of 
{ 125r jTC II-CN-Cbl was 420 pM.a---o, binding to 
the cell surface~·A---A_, total cell-bound [ 125 I} 
TC II at 120 min and e---~ total amount of acid 
l bl 125 d" . . 12 . so u e I-ra ~oact~v&ty at 0 m&n. 
Cbl, similar to the expertrnents in section 4.4.1. 
Figures 6.6 and 6.7 show binding and uptake plus 
degradation of [ 125 r]Tc II-CN-Cbl in the two different series 
of incubations at four concentrations of [125 r] TC II. The 
rate of uptake plus degradation was calculated from the slope 
of the linear part of the curves. When these rates were 
plotted against the concentration of [ 125 r ] TC II-CN-Cbl the 
rate of uptake plus degradation in the absence of unlabeled 
human TC II appeared to be partially saturable (fig. 6.8). 
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fig. 6.6. Effect of concentration of { 125r} TC II-CN-Cbl on 
the binding and uptake plus degradation of { 125r} 
TC II by liver cells; •--e,95 pM; o--08 200 pM; 
B---111 3 400 pM and A---A,600 pM. 
The uptake plus degradation in the presence of unlabeled 
human TC II was not saturable and increased linearly with 
time. The conclusion from these data is that the observed 
uptake plus degradation is the sum of a specific and a 
non-specific process. The non-specific component is 
measured in the presence of unlabeled TC II and the specific 
component is calculated by subtraction of the non-specific 
from the total uptake plus degradation. The specific uptake 
plus degradation became saturated at a level of 1.2 pmole/ 
10 9 cells at a concentration of about 500 pM [ 125 r] TC II-
CN-Cbl. Half-maximal uptake plus degradation occurred at a 
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fig. 6. ?. Effect of the concentration of { 125I} TC II-CN-CbZ 
on the binding and uptake plus degradation of 
(1 25 I} TC II by liver cells in the presence of 
10 nM pure human TC II-CN-CbZ. •--e,95 pM;o--o, 
200 pM; 11--11.,400 pM and A--•,600 pM. 
concentration of 220 pM. When the kinetics of the binding of 
[125 I ] TC II-CN-Cbl were analysed a similar procedure was 
followed. The binding in the absence of unlabeled TC II-CN-
Cbl seemed to be partially saturable and the binding in the 
presence of TC II-CN-Cbl was a linear function of the 
concentration. By subtraction of the binding in the presence 
of unlabeled TC II a curve of saturable specific binding was 
obtained (figure 6 .9). Half-maximal binding was reached at 
a concentration of about 130 pM. 
When the competitive effect of 10 nM human TC II at 400 
pM [ 125 I] TC II-CN-Cbl is compared with the competitive effect 
of 5 nM rat TC II-CN-Cbl (figure 6.6), the conclusion seems 
to be justified that there is no essential difference between 
human and rat TC II with regard to the affinity for the 
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• 
200 400 600 800 
TCII-CN-Cbl (pmoles/1) t 25l 
Of [ 125r) fig. 6.8. The rate of uptake plus degradation 
TC II-CN-Cbl~ represented by the slope of the 
linear part of the curves in the figures 6.6 and 
6.7~ as a function of the concentration of { 125I} 
TC II-CN-Cbl. •--e,rate of uptake plus 
degradation measured in the absence of unlabeled 
TC II-CN-Cbl; •--•,rate of uptake plus 
degradation in the presence of 10 nM unlabeled 
TC II-CN-Cbl; ---,curve of specific uptake plus 
degradation in dependence of the concentration of 
{ 125I} TC II-CN-Cbl_, obtained by subtraction of the 
second curve from the first (top) curve. 
specific binding sites. 
EDTA and EGTA had no effect on the binding, uptake and 
degradation of ( 125 I]Tc II, when studied at about 100 and 
600 pM [125 I]Tc II-CN-Cbl. Both chelators were present in 
a concentration which was 1 mM in excess of the bivalent cat-
ions. Colchicine, which is an inhibitor of microtubular 
function (3), also had no effect on the binding, uptake and 
fig. 6.9. 
r,,,l 
pmoles l U TCII 
bound per 109 cells 
• • 
200 400 600 800 ~ 25D TCII-CN-Cbl (pmoles/1) 
The initiaZ binding of [ 125 I j TC II-C/1-CbZ 
function of the concentration of { 125 I} TC 
as a 
II-GII-
Cbl. Measurements were made in the absence (o--e) 
and in the presence (m---a) of 10 nM unlabeled 
human TC II-CN-Cbl. A curve of saturable specific 
binding was obtained by subtraction of the second 
from the first (top) curve (---). 
degradation of TC II-CN-Cbl. Mannose-6-phosphate, a known 
competitive inhibitor of the uptake process in the secretion-
recapture mechanism of lysosomal hydrolases in fibroblasts 
(4), did not influence the binding, uptake and degradation of 
TC II. This makes it unlikely that the ligand is recognised 
by the binding site through a phosphorylated residue on the 
TC II molecule. 
On the contrary 1 chloroquine inhibited the degradation 
of [ 125r] TC II and caused a compensatory accumulation of 
[ 125r] TC II in the cell (figure 6 .10). The binding remained 
unchanged but the degradation was inhibited to about 50% at 
the concentration of chloroquine used. 
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fig. 6.10. Effect of 3.5 mM chloroquine on the binding~ 
uptake and degradation of { 125I} TC II-CN-Cbl. 
h . rf12s] bl T e concentrat~on o I TC II-CN-C was 
400 pM. Each point is the mean of duplicatg 
measurements. e---•~ binding and uptake in the 
control incubation; •--•~production of acid 
soluble material by the control cells. 0---o, 
binding and uptake in the presence of chloroquine; 
o---D,production of acid soluble material in the 
presence of chloroquine. 
6.5. Discussion. 
The time course of the binding, uptake and degradation 
shows that the TC II-Cbl complex enters the cell in a two-
phase process, a rapid binding onto the outer cell membrane 
followed by a slow but steady uptake of the complex into the 
cell. The binding step is not much influenced by the 
temperature in contrast to the uptake. The appearance of acid 
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soluble !-labeled material in the medium indicates that 
the entered TC II is degraded by proteolytic enzymes in the 
lysosomes. At 4°C such degradation products were completely 
absent, which indicates that it is not an elution of the 
125
r-label. The possibility of extracellular degradation as 
a result of the release of the lysosomal enzymes from dead 
or leaky cells in the medium was excluded by the absence of 
proteolysis during incubation of [ 125 r]Tc II-Cbl in the pre-
sence of sonicated cells at pH 7.4. Proteolysis of TC II 
only occurred, when the pH of the disrupted cell suspension 
was lowered to 5-6. It is highly unlikely that extracellular 
proteolysis occurred in our incubations because the pH was 
kept well at pH 7.4 during the incubation. The degradation 
of [125 I]Tc II during the incubation is therefore a process 
which follows the uptake of the complex into the cell. This 
assumption is supported by the observed effects of NH 4Cl and 
chloroquine on the uptake and degradation of [ 125 I]Tc II-Cbl. 
Both chloroquine and NH 4Cl inhibit proteolysis in the lyso-
somal system presumably by an intralysosomal increase of the 
pH (1,5). It has been reported that 0.05 mM chloroquine 
completely inhibits proteolytic degradation of [ 125 I]Tc II (6) 
low-density lipoprotein (7) and cellular protein (8) in cul-
tured fibroblasts. In our liver cell system 0.05 mM chloro-
quine had no significant effect on uptake and degradation of 
TC II, but at 3.5 mM chloroquine degradation of TC II 
decreased considerably and consequently [ 125 r]TC II accumu-
lated in the cells. The necessity of high concentrations of 
chloroquine in an isolated liver cell system has also been 
reported by Nakai et al. (9) in their studies on the uptake 
and degradation of 125 r-labeled high-density lipoprotein and 
by Tolleshaug et al. (10), who obtained about 75% reduction 
of the degradation of 125 r-labeled asialo-fetuin with 1 mM 
chloroquine. 
Regarding the specificity and saturability.of the 
uptake first the exchangeability of human and rat TC II-CN-
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Cbl was investigated. Our experimental results indicated that 
human and rat TC II-CN-Cbl compete for the same binding sites 
and for the same mechanism of uptake, but also that a part 
of the binding and of the uptake is non-competitive. It 
proved possible to differentiate between competitive and 
non-competitive binding, uptake and degradation by incubations 
at various concentrations of ( 125 I]Tc II-Cbl in the presence 
and absence of an excess of unlabeled human TC II-CN-Cbl. 
From the results it was concluded that the rate of competi-
tive uptake was directly dependent on the degree of occupa-
tion of the specific binding sites. The difference between 
the TC II concentrations, at which half-maximal specific 
binding and uptake plus degradation was reached, 130 pM and 
220 pM, is too small to be used as an argument against this 
conclusion. The non-competitive uptake is probably the result 
of non-specific, non-saturable binding to the cell membrane, 
which otherwise does not mean that specifically and non-spe-
cifically bound TC II molecules are internalized in different 
ways. 
Some TC II will be taken up without previous membrane 
binding by bulk fluid endocytosis. The maximum rate of bulk 
fluid endocytosis observed in cultured fibroblasts was 0.0035% 
per hour of the administered concentration of marker per 10 6 
cells (11). Even if the rate of pinocytosis in rat liver 
cells is much higher than in fibroblasts, it would not be 
sufficient to explain the observed rates of non-specific up-
take. It remains to be established whether or not the non-
specific uptake plays an important role in vivo, also in 
view of the very low concentration of TC II in relation to 
other plasma proteins. 
The studies on the effects of EDTA and EGTA on the bin-
ding and uptake confirmed the observations reported in chap-
ters 3 and 4, that calcium is not needed in the different 
phases of the uptake mechanism. The quantitative data which 
were obtained with iodinated TC II-CN-Cbl correspond well 
with the data from similar experiments with TC rr-( 57co]Cbl, 
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especially after correction for the non-specific processes. 
The non-specific binding and uptake with [ 125 I]Tc II-Cbl 
were higher than in corresponding experiments with partial-
ly purified TC II-[ 57co]cN-Cbl, which may be due to the pro-
tein labeling procedure. 
In conclusion the data from the binding, uptake and 
degradation studies are in agreement with the earlier propo-
sed model of adsorptive endocytosis, followed by lysosomal 
degradation of the transport protein. 
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chapter 7 
GENERAL DISCUSSION 
The purpose of the investigations described in this 
thesis was to obtain a comprehensive picture of the vitamin 
B12 uptake by the liver cell. This process can be divided 
into three aspects, the interaction between the transcobala-
min II-vitamin B12 complex and the plasma me~rane of the 
cell, the transport of the vitamin to the inside of the cell 
and the handling of the vitamin and its transport protein 
within the cell. 
As stated in chapter 3 the high association constant of 
the TC II-Cbl complex and the rapid clearance of free vita-
min B12 by the kidneys make it very unlikely that significant 
amounts of free vitamin B12 are present in the plasma and 
will be taken up by the cells. The plasma transport protein, 
transcobalamin II, is indispensable for an efficient uptake. 
The severe megaloblastic anemia which has been observed in 
patients with a congenital TC II-deficiency, has confirmed 
this concept. 
Our first efforts were directed to the demonstration of 
specific binding sites on the plasma membrane of the rat 
liver. Sucrose- density gradient centrifugation of a liver 
homogenate fraction, which was rich in plasma membranes, 
showed that the profile of the TC Ir-[ 57co]cN-Cbl distribu-
tion over the gradient paralleled the distribution of the 
marker enzyme for plasma membranes. From this it was conclu-
ded that these plasma membranes indeed contained binding 
sites for the complex. The affinity constant and the speci-
fic number of binding sites of isolated plasma membranes 
were determined and the results agreed well with similar 
studies in the literature (1). 
The maximal specific binding of TC rr-[ 57 co]cN-Cbl to 
the plasma membranes was 0.025 pmole per mg of membrane 
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protein and can be expressed as 0.8 pmole per 10 9cells, as-
suming that 2% of the total liver protein is located in the 
8 plasma membranes and that 1 g liver contains about 1.25x 10 
cells {2,3}. The maximal specific binding of TC II-[ 57co]cN-
Cbl and [ 125 r]Tc II-CN-Cbl to the isolated liver parenchymal 
cells were 0.7 and 0.5 pmole/10 9 cells respectively. These 
values agree well with each other and also with the value 
obtained with isolated plasma membranes. Moreover the affini-
ty constants of the binding to the plasma membranes {5-12x 
9 -1 9 -1 10 M } and to the liver parenchymal cells (6-7x 10 M } 
are in good agreement with each other. A similar affinity 
constant (S.Sx 10 9 M- 1} has been described for the binding 
of TC II-( 57co]cN-Cbl to L 1210 lymphoblasts (4). Maximal 
binding to the lymphoblasts was 0.7 pmole per 10 9 cells. In 
cultured fibroblasts a higher affinity constant, 2x 10 10 M- 1 , 
has been found and the maximal binding was about ten times 
higher (5). 
Unsaturated transcobalamin II (apo-TC II} did not com-
pete with the binding of saturated TC II (holo-TC II} to the 
liver plasma membranes. Several authors have reported that 
(pre}incubation of cells or membrane fractions with apo-TC II 
inhibited the binding or uptake of the labeled holo-TC II (1, 
6}. Recently Hall and Green described that the uptake of 
TC II-vitamin B12 by Hela-cells and lyQphocytes was unaffec-
ted by apo-TC II , but that the binding of holo-TC II, measu-
red at 4°C, was competitively inhibited by apo-TC II (7). They 
suggested that, although apo-TC II and holo-TC II compete 
for the same binding sites on the plasma membrane, different 
mechanisms exist for their entrance into the cell. Because 
of the differences in the experimental conditions in the 
various studies it is not possible to decide for or against 
competitive inhibition. Our results, which are partially 
supported by the observations of Hall and Green (7), suit 
the physiological circumstances better, because the excess 
of apo-TC II should not be able to block the uptake of holo-
TC II by the cell. 
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The second aspect of the vitamin B12 uptake, the trans-
port of the vitamin molecule into the cell, was studied with 
isolated liver cells. The uptake and the binding consisted of 
a specific and a non-specific component. Because it is not 
clear to what extent the non-specific processes occur in vivo, 
we will confine ourselves to the data on the specific satu-
rable uptake. 
The rate of specific uptake of TC rr-( 57co]cN-Cbl at 
saturation was 1.1 pmole/10 9 cells/hour and of ( 125 r)Tc II-
CN-Cbl amounted to about 0.7 pmole/10 9 cells/hour. However, 
these values do not include the radioactivity which had been 
taken up and released again. For TC rr-[ 57co]cN-Cbl an esti-
mate of the total uptake can be obtained from the incubations 
in the presence of chloroquine. The rate of uptake at 400 pH 
TC Ir-[ 57co]cN-Cbl was roughly 2.6 times the uptake in the 
absence of chloroquine. Assuming that the effects of chloro-
quine in specific and non-specific uptake are the same, the 
real rate of specific uptake of TC Ir-[ 57co}cN-Cbl would be 
9 ' 
about 2.9 pmoles/10 cells per hour. This value should 
correspond with the rate of specific 
'125 l of l I TC II-CN-Cbl at saturation, 
uptake plus degradation 
which was 1.2 pmole/10 9 
cells per hour. The latter value is somewhat lower but diffe-
rences in the individual cell preparations may account for 
this. Consequently the uptake plus degradation of [ 125I]Tc II-
CN-Cbl in the presence and in the absence of chloroquine has 
to be nmgly the same. In fact they were 4.4 and 3.9 pmoles/ 
10 9 cells respectively after one hour of incubation in the 
same cell population, which agrees with the presupposition. 
The maximal rates of specific uptake in the liver cells 
are lower than the the comparable values for L 1210 lympho-
bloasts. DiGirolamo and Huennekens {4) observed a maximal 
uptake of 0.4 pmole TC rr-[ 57co]cN-Cbl/l0 9 cells per min and 
9 Ostroy and Garns {8) reported a value of 18 prnoles/10 cells 
per min. In fibroblasts the kinetics of the uptake have not 
been analysed, but it is possible to deduce from the figures 
that after an incubation of 6 hours about 5 prnoles/10 9 cells 
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are associated with the cell, of which 25% is bound to the 
surface of the cells, and 5-6 pmoles are secreted as small 
molecular weight degradation products (5). 
On the basis of the data on binding, uptake and degra-
dation of TC II-CN-Cbl it was attempted to construct a model 
for the mechanism of uptake. In chapter 3 three different 
models have been proposed: 
1. the vitamin molecule enters the cytoplasm of the cell 
through the membrane after dissociation from its trans-
port protein on the surface of the cell. 
2. the whole TC II-vitamin B12 complex enters the cytoplasm 
of the cell through the membrane. 
3. the TC II-vitamin B12 complex is taken up by the cell in 
a pinocytotic process. 
There are no arguments in favour of the first model. 
Several authors have demonstrated that the TC II molecule is 
consumed during the uptake process and that re-utilization, 
analogous to e.g. transferrin, does not occur (6,9). Re-uti-
lization would be a logical consequence of this model. 
The second model is supported by Gams and coworkers, 
who presented three arguments in favour of this model: 1. 
the presence of TC II-vitamin B12 in the cytoplasm of 
L 1210 lymphoblasts (10); 2. a TC II dependent uptake of 
vitamin B12 by isolated mitochondria (11); 3. the kinetics 
of the uptake of TC II-Cbl by L 1210 lymphoblasts, which 
showed in their studies no separate processes of binding and 
uptake but a smooth continuous increase with time of cell 
associated radioactivity (8). An argument against a TC II-
mediated uptake by mitochondria is the passive but specific 
uptake mechanism for free OH-Cbl in isolated mitochondria, 
which has been reported by Fenton et al. (12). They conclu-
ded that the concentration of vitamin B12 in the mitochon-
dria takes place as a result of the binding to an intramito-
chondrial protein. 
With the same L 1210 lymphoblasts DiGirolamo and 
Huennekens (4) did find a biphasic pattern of binding and 
uptake. The affinity constant of the binding of TC II-Cbl to 
the lymphoblasts was similar to the affinity constant of the 
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binding to the isolated liver cells in our study. However, 
half-maximal binding and half-maximal uptake did not occur 
at the same concentration of TC II-Cbl. This observation may 
indicate that in the lymphoblasts the binding is not functi-
onally linked to the uptake, thereby precluding a process of 
pinocytosis, or that the extracellular concentration of TC II-
Cbl has an effect on the efficiency of internalization of 
the TC II-Cbl complex through pinocytosis or on the rate of 
pinocytosis itself. 
The third model, involving binding to the plasma membra-
ne, pinocytosis and lysosomal degradation, has been supported 
by in vivo experiments of Schneider et al. (6), who demonstra-
ted that in the rabbit [ 125 I]Tc II-Cbl is broken down by the 
tissues. Further evidence for this model has been presented 
by the experiments of Youngdahl-Turner (5), which demonstra-
ted that internalized TC II was degraded in the lysosomes 
of cultured fibroblasts. 
Our experimental results are in best accordance with th~ 
third model. First of all we have demonstrated that TC II is 
broken down by proteolysis in the lysosomes and the usual 
way for an extracellular protein to arrive in the lysosomes 
is by way of an endocytic process (13). Second, chloroquine 
inhibited the degradation of TC II and caused a compensatory 
accumulation of TC II and of Cbl in the cell, probably in 
the lysosomes. This observation precludes the possibility 
that TC II is broken down in the lysosomes after it has deli-
vered its vitamin molecule to, for instance, the mitochondria. 
In the third place the kinetics of binding and uptake sug-
gest a mechanism of pinocytosis. Half-maximal binding and 
half-maximal uptake, and saturation of binding and of uptake 
occur at about the same extracellular concentration of TC II-
Cbl, which indicates that the degree of occupation of the 
membrane binding sites primarily determines the rate of up-
take of the TC II-Cbl complex. 
Analysing the kinetics of TC II-Cbl uptake by the liver 
cells it was assumed that the rate of formation of pinocyto-
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tic vesicles is constant during the incubation and not affec-
ted by the binding of the ligand to the binding site. In the 
literature there is evidence that the ingestion of particles 
by a pinocytotic process is enhanced by the binding of the 
particle to the membrane and that bivalent or multivalent 
macromolecules, such as concanavalin A and immunoglobulins, 
stimulate the rate of pinocytosis by their binding to the 
cell surface. When the same macromolecules were made uni-
valent, stimulation was absent although the binding was not 
affected. It is therefore unlikely that the TC II molecule, 
which is thought to be univalent, is able to influence the 
rate of pinocytosis of the liver cells. 
A consequence of the quantitative data of binding and 
uptake by the liver cell is, that each membrane binding site 
allows the entrance of 2-4 TC II-Cbl molecules per hour. 
Assuming that the binding sites are evenly distributed over 
the total cell surface, and that no direct relation exists 
between the site of pinocytosis and the localization of the 
binding sites, a membrane turnover of 2-4 times per hour 
would be necessary, as a result of the pinocytotic process, 
to reach the observed rate of uptake. The rate of pinocyto-
sis in the liver cells, which was measured by plasma membrane 
protein turnover studies by Schimke (14}, appears to be only 
25% of the plasma membrane surface per hour. Two different 
explanations for this discrepancy between membrane turnover 
and rate of uptake of extracellular protein have been given 
by Neville and Chang (15}: first the occurrence of receptor 
clustering at the site of pinocytosis and second a high de-
gree of re-utilization of membrane components, which means 
that the rates of plasma membrane protein turnover cannot be 
used as a measure for rates of pinocytosis. So far no con-
vincing evidence has been given for any of the two models, 
although Anderson et al. (16} concluded from electron 
microscopic studies on the binding of ferri tin-_conjugated 
low-density lipoprotein (LDL) to fibroblasts, that the LDL-
binding sites were concentrated in so-called coated regions, 
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figure 7. 1. 
CLUSTERED BINDING-SITE-MEDIATED PINOCYTOTIC TRANSPORT MODEL FOR 
TRANSCOBALAMIN II- VITAMIN B12 IN THE LIVER PARENCHYMAL CELL 
TC II CbL 0 + 
Q 
TC II - CbL 
G 
coated region 
\:::1. 
coated 
pinocytati c 
vesicle 
( 
I 
I 
I 
.,..---
~ I ®Q® 
0 ~ secundory : primacy lysosome I lysosome J cytoplasma ++,......I 
. I 
proteolytic 0 
1
1: 
enzyme 
.. -
mitochondrion 
protein 
degradation 
products 
~/+ 
133 
which accounted for only 1.4% of the total membrane surface 
area. 
Clustering of the binding sites for TC II on the liver 
plasma membrane could explain the observed rates of uptake. 
Consequently .the scheme for the uptake of TC II-vitamin B12 
might be as illustrated in figure 7.1. First the TC II-
vitamin B12 complex adheres to the clustered binding sites 
on coated regions in the plasma membrane, which are predes-
tined to become sites of pinocytosis. After formation of the 
pinocytotic vesicle fusion with the primary lysosomes occurs 
and a secondary lysosome is formed. Meanwhile the TC II mole-
cule is degraded by the lysosomal proteolytic enzymes and 
the vitamin B12 molecule is detached from its binding pro-
tein. The vitamin B12 molecule is probably transfered to the 
cytoplasm and the mitochondria and will be converted to the 
respective coenzyme forms. A large part of the internalized 
vitamin is released by the cell, possibly after conversion 
into biologically active forms. 
In conclusion the mechanism of uptake of transcobalamin-
II-vitamin B12 by the liver cell can be described as 
adsorptive endocytosis followed by lysosomal fusion and pro-
teolytic degradation of the transport protein. Quantitative 
aspects of the kinetics of binding and uptake suggest a clus-
tering of the binding sites in small areas of the plasma mem-
brane. From the kinetic analysis of binding, uptake and 
release we concluded that at a normal TC II-Cbl concentration 
in the blood plasma the majority of the binding sites on the 
liver plasma membranes are occupied with holo-TC II and that 
TC II-Cbl is continuously taken up and released. A small 
fraction of the internalized vitamin B12 is probably retained 
by the cell to compensate for the continuous release of vita-
min from the storage pool. In our studies no arguments have 
been found that the exchange between intra- and extracellular 
vitamin B12 is regulated by the cell on the basis of the 
extracellular concentration of TC II-vitamin B12 . 
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SUMMARY 
The object of the experiments, described in this thesis, 
was to obtain a comprehensive picture of the uptake of 
vitamin B12 by the liver cell, and of the handling of the 
vitamin and its plasma transport protein, transcobalarnin II, 
in the cell. Chapter 1 gives a synopsis of the literature 
on vitamin B12 transport and metabolism and describes the 
different models which have been proposed for the mechanism 
of the vitamin B12 uptake by the cell. In chapter 2 the 
various techniques are described, which have been used 
throughout the investigations. The first aspect of the 
uptake process, the binding of the TC !!-vitamin B12 complex 
to the cell membrane, is treated in chapter 3. The presence 
of specific binding sites on the isolated liver plasma 
membrane was demonstrated and the kinetic aspects of the 
binding process were studied. An affinity constant of 
5-10xl0 9 M-l was determined, which suggests that in vivo 
the majority of the binding sites on the cell surface is 
occupied by TC !!-vitamin B12 at a normal plasma TC !!-
vitamin B12 concentration of about 500 pM. Free vitamin B12 
and apo-TC II had no competitive effect on the binding of 
holo-TC II. In contrast with the binding of TC !!-vitamin 
B12 to various other cells, the binding to the liver cell 
membranes did not depend on the presence of calcium or 
magnesium ions. It appeared to be possible to reduce the 
binding capacity of the plasma membranes by preincubation 
either with trypsin or with detergents, which indicates that 
an essential part of the binding sites is composed of protein. 
The phase which follows the binding of the complex to 
the binding sites is its transfer to the interior of the 
cell. This is discussed in the chapters 4 and 6. In chapter 
4 experiments are 
TC !!-vitamin B12 
described which were carried out with a 
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complex, Co-labeled in the vitamin 
moiety, and in chapter 6 the fate of the transport protein 
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is studied with radioactive iodine labeled TC II-vitamin 
B12 . The incorporation of the radioactive label in the 
protein moiety of the complex necessitated the purification 
of TC II to homogeneity. For this purpose an affinity 
chromatography teohnique was developed, which is easy to 
perform and apparently does not harm the protein structure. 
2.7 mg of TC II-CN-Cbl were purified from 20 kg of Cohn 
fraction III, prepared from 500 1 human plasma. The final 
yield was about 50% and the specific binding capacity 
amounted to 0.98 mol CN-Cbl per mol TC II. 
Studies on the cellular uptake were performed by incu-
bations of TC II-CN-Cbl complex with isolated liver paren-
chymal cells in suspension. During the incubations a fast 
increase of cell-bound radioactivity was observed in the 
first few minutes and this phase was followed by a steady 
linear increase in the next two hours. This pattern suggests 
a rapid binding of the complex onto the surface of the cell 
and a relatively slow internalization of the TC II-Cbl com-
plex. Both binding and uptake were partially saturable with 
increasing extracellular TC II-CN-Cbl concentrations. The 
assumption was made that the observed uptake is the sum of 
a specific and a non-specific process, which was confirmed 
by the results of incubations in the presence of an excess 
of unlabeled TC II-CN-Cbl. Under these circumstances the 
specific binding and uptake form only a small, negigible 
fraction of the total uptake,and the main uptake is there-
sult of the non-specific process. The specific saturable 
binding and uptake were calculated by subtraction of the 
non-specific from the total binding and uptake. 
Binding and uptake reached half-maximal levels and sa-
turation at about the same concentrations of TC II-CN-Cbl, 
which suggests that the rate of uptake is primarily deter-
mined by the degree of occupation of the available binding 
sites on the cell membrane. 
The uptake of TC II is accompanied by the formation and 
secretion of small molecular weight degradation products of 
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the TC II molecule. Addition of chloroquine, a known inhibi-
tor of intralysosomal proteolytic enzymes, to the incubation 
system led to an accumulation of the transport protein and 
the vitamin within the cell and to a reduction of proteolysis 
of TC II-Cbl. This suggests that proteolysis of TC II in the 
lysosomes is a prerequisite for the normal cellular handling 
of vitamin B12 . Moreover, it indicates that the observed 
uptake of vitamin B12 is not representative for the total 
uptake but only the resultant of a process of uptake and of 
release. This conclusion was confirmed by observations on the 
release of vitamin B12 by isolated liver cells which were 
loaded with radioactive vitamin B12 shortly before their iso-
lation. These experiments suggest that vitamin B12 which is 
bound to the surface of the cells or has been taken up in the 
pinocytotic vesicles and in the lysosomes, can be released 
completely by the liver cells during short incubations. 
However, when the radioactive vitamin B12 was administered 
70 hours before the isolation of the liver cells, only 15% 
of the radioactive vitamin was released during two hours of 
incubation. The same percentage was found when the release 
of total intracellular vitamin B12 into the medium was deter-
mined. This observation indicates that after 70 bours the 
internalized vitamin B12 is taken up in the vitamin B12 
storage pool of the liver. 
Summarizing all qualitative and quantitative data from 
the various experiments the whole rat liver is able to bind 
0.5 to 0.7 pmole and to internalize about 2.3 pmoles of TC II-
CN-Cbl per hour from which about 2/3 is released again. 
Concomittantly the transport protein is degraded in the lyse-
somes and secreted as small molecular weight degradation 
products. This suggests that TC II-vitamin B12 is internali-
zed by means of adsorptive endocytosis or binding site- media-
ted pinocytosis, followed by fusion of the endocytic vesicles 
withe the lysosomal system. 
On the basis of the relation between the amount of bin-
ding sites and the observed rate of uptake each binding site 
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should be able to internalize 2-4 molecules of TC II-Cbl per 
hour. In terms of plasma membrane turnover rates this impli-
cates that either the binding sites are subject to a high 
degree of re-utilization or the binding sites are mainly con-
centrated in small areas of the cell surface or both. 
Concentration of binding sites in so-called coated regions 
have been described earlier for low-density lipoprotein recep-
tors on fibroblast membranes. The mechanism of the uptake of 
TC II-Cbl by the liver parenchymal cell can therefore most 
likely be defined as clustered binding site- mediated pino-
cytosis. 
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SAMENV ATTING 
De experirnenten waarvan de resultaten in dit proef-
schrift zijn beschreven hadden tot doel een sarnenvattend 
beeld te krijgen van de opname van vitarnine 8 12 vanuit het 
plasma door de levercel en van de verdere verwerking binnen 
die eel. In hoofdstuk l wordt een overzicht gegeven van 
historische ontwikkelingen in het onderzoek naar het 
vitamine B12 transport en metabolisrne in het algemeen en 
van de cellulaire opnarne processen in het bijzonder. 
de 
Ook de isolatie en karakterisatie van het plasma transport-
eiwit, transcobalarnine II, krijgen ruim aandacht. Uit die 
vele gegevens, afkomstig van experimenten met verschillende 
celtypen en onder diverse experirnentele omstandigheden,werden 
de volgende conclusies getrokken: 
l. Transeobalamine II is een vitamine B12 bindend plasma-
eiwit met een moleeulairgewieht van 38 000 1 dat een onmis-
bare rol vervult in de opname van vitarnine B12 door de 
eel. 
2. Op de buitenmembraan van de eel bevinden zieh bindings-
plaatsen voor het transeobalamine II-vitamine B12 complex. 
3. Het transeobalamine II-vitarnine B12 complex wordt in zijn 
geheel door de eel opgenomen en het transporteiwit gaat 
bij dit proces verloren, vermoedelijk door proteolytische 
afbraak in de lysosornen. 
4. De opgenomen vitamine wordt voor een deel weer vrij snel 
door de eel uitgescheiden. In fibroblasten is dit ten dele 
afhankelijk van de aanwezigheid van een intraeellulair 
vitamine B12 bindend eiwit. 
De literatuurgegevens zijn op een aantal punten min of meer 
met elkaar in tegenspraak. Oat betreft ten eerste de 
calciumafhankelijkheid van de binding van het transcobalarnine 
II-vitarnine B12 complex aan de bindingsplaatsen op de plasma-
rnembraan. Ten tweede worden tegenstrijdige resultaten 
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beschreven aangaande het competitieve effect van onverzadigd 
of apo-transcobalamine II ten opzichte van verzadigd of 
holo-TC II. Een derde controverse kan worden waargenomen 
in de beschrijving van de intracellulaire verwerking van 
het TC II-vitamine B12 complex, waarin het model van lyso-
somale afbraak van TC II, gevolgd door intrede van de 
vrije vitamine B12 molecule in het cytoplasma, en het model 
van direct transport van het intacte complex naar het cyto-
plasma, gevolgd door een TC II afhankelijke opname van de 
vitamine B12 molecule door de mitochondrien, tegenover 
elkaar staan. 
In het nu volgende overzicht van de resultaten uit dit 
proefschrift wordt duidelijk gemaakt aan welke karakteris-
tieken de opname door de levercel voldoet. 
In hoofdstuk 3 wordt aannemelijk gemaakt dat lever-
cellen op hun plasmamembraan specifieke bindingsplaatsen 
bezitten. De affiniteit van transcobalamine II-vitamine B12 
ten opzichte 
s a. 10 x 10 9 
van deze bindingsplaatsen ligt in de orde van 
-1 M . Deze waarde doet vermoeden dat bij een 
plasma concentratie aan TC II-vitamine B12 van + 500 pM 
het merendeel van deze bindingsplaatsen op de membraan bezet 
is. De affiniteit van de bindingsplaatsen in diverse 
weefsels vertoont weinig onderlinge verschillen. De binding 
van TC II-vitamine B12 wordt niet belnvloed door de aanwezig-
heid van vrije vitamine B12 of van apo-TC II en de binding 
is niet afhankelijk van calcium- of magnesiumionen. Het bleek 
mogelijk het aantal bindingsplaatsen sterk te reduceren door 
incubaties van de membraanpreparaten met trypsine en met 
detergentia. Hieruit mag de conclusie worden getrokken dat 
een essentieel onderdeel van de bindingsplaats is opgebouwd 
uit eiwit. 
De fase, die volgt op de binding van het complex aan 
de plasmamembraan, is het transport de eel in en wordt 
beschreven in de hoofdstukken 4 en 6. Hoofdstuk 4 betreft 
opnamestudies met gelsoleerde rattelever parenchymcellen, 
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die zijn uitgevoerd met een TC II-vitamine B12 complex dat 
radioactief gemerkt is in het vitamine B12 gedeelte. In 
hoofdstuk 6 worden vergelijkbare experimenten vermeld die 
zijn uitgevoerd met de radioactieve merking in het eiwit-
gedeelte. 
Tijdens incubatie van een levercel suspensie met het 
radioactief gemerkte TC II-vitamine B12 wordt in de eerste 
minuten een sterke stijging van celgebonden radioactiviteit 
waargenomen, en deze eerste fase wordt gevolgd door een 
tweede fase van geleidelijke lineaire toename van de cel-
gebonden activiteit. Dit patroon suggereert een snelle 
binding van het TC II-vitamine B12 complex aan het cel-
oppervlak en een relatief langzaam transport de eel in. 
Zowel binding als opname vertonen met stijgende TC II-
vitamine B12 concentraties een gedeeltelijke verzadiging. 
Het vermoeden dat we hier te maken hebben met een combinatie 
van een specifiek en een niet-specifiek proces, wordt 
bevestigd door de resultaten van incubaties in aanwezigheid 
van een overmaat aan ongemerkt TC II-vitamine B12 . Onder die 
omstandigheden worden alleen de niet-specifieke binding en 
opname gemeten en deze blijken met toenemende gemerkte TC II-
vitamine B12 concentraties lineair toe te nemen. Uit de 
combinatie van beide proefopzetten is het mogelijk de 
specifieke verzadigbare component van de binding en de opname 
afzonderlijk te berekenen. De overeenkomst tussen de 
concentratie-afhankelijkheid van de binding en van de opname 
geeft aan, dat de opnamesnelheid primair wordt bepaald door 
de bezettingsgraad van de beschikbare bindingsplaatsen op de 
celmembraan. 
De opname van TC II gaat gepaard met de vorming en 
uitscheiding van klein-moleculaire afbraakprodukten van de 
TC II molecule. Toevoeging van chloroquine, een remmer van 
intralysosomale proteolytische enzymen, aan het incubatie 
systeem leidt tot een accumulatie van het transporteiwit 
en van de vitamine B12 . De som van opname en afbraak van 
143 
TC II wordt nauwelijks door chloroquine belnvloed. Hieruit 
wordt de conclusie getrokken, dat de waargenomen opname van 
vitamine B12 in feite slechts de hoeveelheid vitamine B12 
weergeeft die na opname in de eel achterblijft, en dat in 
afwezigheid van chloroquine het grootste deel van de 
opgenornen vitamine B12 de eel weer verlaat. Deze conclusie 
wordt bevestigd door experimenten, waarin de uitscheiding 
van vitarnine B12 door gelsoleerde levercellen wordt bestu-
deerd, nadat deze cellen v66r hun isolatie in vivo zijn 
opgeladen met radioactief gemerkte vitarnine B12 . Wanneer 
de in vivo toediening heeft plaatsgevonden 30 min voor de 
aanvang van de celisolatie, wordt radioactief gernerkte 
vitarnine vrijwel volledig uitgescheiden gedurende een 
incubatie van 2 uur. Heeft de in vivo oplading 70 uur 
tevoren plaatsgevonden dan wordt slechts + 15% gedurende 
een 2-uurs incubatie uitgescheiden. 
Hoofdstuk 5 beschrijft de isolatie van transcobalamine 
II uit humaan plasma. Deze isolatie is een essentieel onder-
deel van het totale onderzoek,omdat selectieve radioactieve 
merking van het transporteiwit slechts mogelijk is, indien 
het te merken materiaal volledig zuiver is. Om dit doel te 
bereiken werd een affiniteitschromatografie techniek 
ontwikkeld, die eenvoudig uitvoerbaar is, tot een efficiente 
zuivering leidt en geen schadelijke invloed op het te 
zuiveren eiwit heeft. Uit 20 kg Cohn's fractie III van 
+ 500 1 humaan plasma \verd, met een opbrengst van 50%, 
2,7 rng zuiver transcobalarnine II met een specifieke binding 
van 0,98 mol CN-Cbl/mol TC II gelsoleerd. Door middel van 
electroforetische analyses van het gezuiverde produkt blijkt 
dat het enigszins heterogeen van samenstelling is. Het is 
mogelijk een deel van het rnateriaal door reductie met s-
mercaptoethanol en dithiothreltol in 2 sets van 2 complernen-
taire fragmenten op te splitsen. Of de fragmenten natuurlijk 
voorkomende subunits zijn of dat zij het gevolg zijn van 
proteolyse of een andere invloed van buitenaf, valt uit 
144 
onze resultaten niet op te maken. Met behulp van iso-
electrische focussering van het zuivere eiwit blijkt het 
mogelijk het eiwit te scheiden in op zijn minst vier 
verschillende subfracties. Dit sluit aan bij recente 
gegevens aangaande de genetische variabiliteit van trans-
cobalamine II. 
In hoofdstuk 7 worden de resultaten van alle in dit 
proefschrift beschreven experimenten aan elkaar getoetst en 
als bouwstenen gebruikt voor een model van de opname van 
vitamine B12 door de levercel. In dit model is de volgorde 
van gebeurtenissen als volgt: 
1. TC II-vitamine B12 bindt zich aan specifieke bindings-
plaatsen op het celoppervlak, die op grand van 
kwantitatieve gegevens waarschijnlijk in zogenaamde 
''clusters'' geconcentreerd zijn. 
2. Met een gedeelte van de membraan wordt het hele complex 
via pinocytose de eel binnengevoerd. 
3. Het pinocytose-blaasje vervloeit met het lysosomale 
systeem, waarna door inwerking van lysosomale proteoly-
tische enzymen het transporteiwit wordt afgebroken en 
vitamine B12 wordt vrijgemaakt. 
4. De vitamine B12 molecule komt via onbekende wegen terecht 
in het cytoplasma en het mitochondrion of wordt door de 
eel uitgescheiden. 
Transcobalamine II schaart zich daarmee in de rij van ei-
witten, waarvoor een vergelijkbaar opnamemechanisme reeds 
eerder werd waargenomen, zoals asialoglycoproteinen, "high-
and low-density" lipoproteine en lysosomale hydrolases 
in fibroblasten. 
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Op de omslag is een foto weergegeven van 
geisoleerde rattelever parenchymceZZen~ gezien 
door een fase-contrastmicroscoop. 
